,coef,coef_graph,coef_combined,coef_combined_zscore,coef_combined2
5-Phosphoribose 1-diphosphate biosynthesis,2.8575695e-08,2.0,2.8575695e-08,-0.15826938,0.054844163
ABC transporters in lipid homeostasis,0.0004442946,2.0,0.0004442946,0.10259996,0.2418647
ADP signalling through P2Y purinoceptor 1,4.0603776e-05,2.0,4.0603776e-05,-0.13444395,0.0719249
ADP signalling through P2Y purinoceptor 12,0.00011771858,2.0,0.00011771858,-0.08916278,0.10438756
AKT phosphorylates targets in the cytosol,0.00011955342,2.0,0.00011955342,-0.088085376,0.10515996
AKT phosphorylates targets in the nucleus,0.0007706455,2.0,0.0007706455,0.29423052,0.37924707
AKT-mediated inactivation of FOXO1A,3.5800679e-06,2.0,3.5800679e-06,-0.15618397,0.056339215
ALKBH2 mediated reversal of alkylation damage,9.449362e-10,2.0,9.449362e-10,-0.1582856,0.05483252
ALKBH3 mediated reversal of alkylation damage,3.6018672e-08,2.0,3.6018672e-08,-0.158265,0.054847296
AMER1 mutants destabilize the destruction complex,1.1192805e-05,3.0,1.1192805e-05,-0.15171383,-0.4929008
AMPK inhibits chREBP transcriptional activation activity,2.5399477e-05,2.0,2.5399477e-05,-0.1433718,0.06552443
APC/C-mediated degradation of cell cycle proteins,8.272156e-06,5.0,8.272156e-06,-0.15342882,-1.5990196
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway,5.2849007e-08,2.0,5.2849007e-08,-0.15825512,0.054854374
ARL13B-mediated ciliary trafficking of INPP5E,1.3802932e-07,2.0,1.3802932e-07,-0.1582051,0.054890238
ATF4 activates genes,1.1816656e-08,2.0,1.1816656e-08,-0.15827921,0.054837108
ATF6 (ATF6-alpha) activates chaperone genes,7.1070403e-06,2.0,7.1070403e-06,-0.15411296,0.057823945
ATP sensitive Potassium channels,7.091738e-08,2.0,7.091738e-08,-0.1582445,0.05486199
AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00014861688,2.0,0.00014861688,-0.07101955,0.11739467
"AXIN mutants destabilize the destruction complex, activating WNT signaling",2.2370734e-09,3.0,2.2370734e-09,-0.15828484,-0.4976116
Abacavir metabolism,9.40801e-08,2.0,9.40801e-08,-0.1582309,0.054871738
Abacavir transmembrane transport,0.0,2.0,0.0,-0.15828615,0.054832134
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,6.292892e-10,2.0,6.292892e-10,-0.15828578,0.054832403
Acetylation,0.0,2.0,0.0,-0.15828615,0.054832134
Acetylcholine Neurotransmitter Release Cycle,1.7738888e-06,2.0,1.7738888e-06,-0.15724455,0.05557887
Acetylcholine binding and downstream events,9.70356e-09,2.0,9.70356e-09,-0.15828046,0.05483621
Acetylcholine regulates insulin secretion,2.0603938e-08,2.0,2.0603938e-08,-0.15827405,0.054840807
Acrosome Reaction,0.0,2.0,0.0,-0.15828615,0.054832134
Activated NOTCH1 Transmits Signal to the Nucleus,0.0006993066,2.0,0.0006993066,0.2523409,0.34921587
Activation and oligomerization of BAK protein,1.1227793e-10,2.0,1.1227793e-10,-0.15828608,0.05483218
Activation of ATR in response to replication stress,1.1617957e-07,2.0,1.1617957e-07,-0.15821794,0.05488104
Activation of BH3-only proteins,9.372e-06,6.0,9.372e-06,-0.152783,-2.1510012
Activation of C3 and C5,0.0,2.0,0.0,-0.15828615,0.054832134
Activation of Matrix Metalloproteinases,4.3561424e-05,2.0,4.3561424e-05,-0.13270725,0.07316997
Activation of NMDA receptor and postsynaptic events,1.8413402e-05,3.0,1.8413402e-05,-0.14747395,-0.48986116
Activation of PPARGC1A (PGC-1alpha) by phosphorylation,5.3788212e-06,2.0,5.3788212e-06,-0.15512775,0.057096425
Activation of RAC1,1.0592446e-06,2.0,1.0592446e-06,-0.15766418,0.055278033
Activation of SMO,6.679484e-05,2.0,6.679484e-05,-0.11906478,0.082950436
Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.00023175518,2.0,0.00023175518,-0.022201426,0.15239301
Activation of kainate receptors upon glutamate binding,7.854591e-06,3.0,7.854591e-06,-0.153674,-0.4943061
Activation of the pre-replicative complex,4.8326797e-07,2.0,4.8326797e-07,-0.15800238,0.055035565
"Activation, myristolyation of BID and translocation to mitochondria",9.749125e-05,2.0,9.749125e-05,-0.101040095,0.09587255
"Activation, translocation and oligomerization of BAX",7.63195e-05,2.0,7.63195e-05,-0.11347198,0.08695999
Adherens junctions interactions,2.0442406e-10,2.0,2.0442406e-10,-0.15828604,0.05483222
Adrenaline signalling through Alpha-2 adrenergic receptor,2.6915345e-06,2.0,2.6915345e-06,-0.15670572,0.05596517
"Adrenaline,noradrenaline inhibits insulin secretion",1.4638523e-06,2.0,1.4638523e-06,-0.15742658,0.055448372
Advanced glycosylation endproduct receptor signaling,1.1394098e-05,2.0,1.1394098e-05,-0.15159564,0.059628643
Aflatoxin activation and detoxification,8.195819e-08,2.0,8.195819e-08,-0.15823804,0.054866627
Agmatine biosynthesis,0.0,2.0,0.0,-0.15828615,0.054832134
Amine Oxidase reactions,0.0,3.0,0.0,-0.15828615,-0.49761257
Amino Acid conjugation,3.9182072e-05,2.0,3.9182072e-05,-0.13527876,0.07132642
Amino acid transport across the plasma membrane,9.6508475e-06,2.0,9.6508475e-06,-0.15261926,0.058894802
Amplification of signal from the kinetochores,1.141629e-06,2.0,1.141629e-06,-0.1576158,0.05531272
Amyloid fiber formation,0.036061227,2.0,0.036061227,21.016567,15.235354
Anchoring fibril formation,0.0,2.0,0.0,-0.15828615,0.054832134
Anchoring of the basal body to the plasma membrane,0.0020712821,2.0,0.0020712821,1.0579536,0.92676985
Antagonism of Activin by Follistatin,3.6632488e-07,2.0,3.6632488e-07,-0.15807106,0.05498634
"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",5.247179e-09,2.0,5.247179e-09,-0.15828308,0.05483434
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,7.287721e-07,2.0,7.287721e-07,-0.15785824,0.055138916
Antigen processing-Cross presentation,1.4509568e-06,5.0,1.4509568e-06,-0.15743418,-1.6018912
Antigen processing: Ubiquitination & Proteasome degradation,4.016452e-05,2.0,4.016452e-05,-0.13470188,0.071739994
Antiviral mechanism by IFN-stimulated genes,3.8108753e-06,2.0,3.8108753e-06,-0.15604843,0.056436386
Apoptosis induced DNA fragmentation,4.4053418e-06,2.0,4.4053418e-06,-0.15569939,0.056686625
Apoptotic cleavage of cellular proteins,0.0006097639,4.0,0.0006097639,0.19976217,-0.7933678
Apoptotic factor-mediated response,2.1018278e-07,3.0,2.1018278e-07,-0.15816273,-0.4975241
Arachidonate production from DAG,5.526105e-07,2.0,5.526105e-07,-0.15796167,0.055064768
Arachidonic acid metabolism,7.338672e-10,9.0,8.15408e-11,-0.15828611,-3.8122802
Aryl hydrocarbon receptor signalling,2.4616216e-07,2.0,2.4616216e-07,-0.15814161,0.054935753
Assembly of active LPL and LIPC lipase complexes,1.7972029e-06,2.0,1.7972029e-06,-0.15723085,0.055588685
Assembly of the pre-replicative complex,0.0027477695,4.0,0.0027477695,1.4551814,0.10665807
Association of TriC/CCT with target proteins during biosynthesis,0.0004623918,2.0,0.0004623918,0.11322649,0.24948299
Astrocytic Glutamate-Glutamine Uptake And Metabolism,7.1051804e-09,2.0,7.1051804e-09,-0.15828198,0.05483512
Attachment of GPI anchor to uPAR,0.00012756087,2.0,0.00012756087,-0.08338347,0.10853082
B-WICH complex positively regulates rRNA expression,1.5081548e-09,2.0,1.5081548e-09,-0.15828526,0.054832768
BBSome-mediated cargo-targeting to cilium,2.9270745e-05,2.0,2.9270745e-05,-0.14109862,0.067154095
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,0.00010563515,2.0,0.00010563515,-0.09625807,0.09930086
"BMAL1:CLOCK,NPAS2 activates circadian gene expression",1.1473e-07,2.0,1.1473e-07,-0.15821879,0.054880433
Basigin interactions,0.00924211,2.0,0.00924211,5.2686043,3.9454393
Beta-catenin phosphorylation cascade,0.00019954031,2.0,0.00019954031,-0.04111773,0.13883166
Bicarbonate transporters,8.433435e-05,2.0,8.433435e-05,-0.10876573,0.09033396
Bile acid and bile salt metabolism,3.545715e-07,3.0,3.545715e-07,-0.15807796,-0.49746335
Biosynthesis of DHA-derived SPMs,1.7754962e-06,6.0,1.7754962e-06,-0.1572436,-2.1541991
Biosynthesis of DPA-derived SPMs,5.6381227e-06,3.0,5.6381227e-06,-0.1549755,-0.49523914
Biosynthesis of EPA-derived SPMs,7.5453216e-05,3.0,7.5453216e-05,-0.11398064,-0.4658494
Biosynthesis of electrophilic Ï‰-3 PUFA oxo-derivatives,6.1614465e-09,2.0,6.1614465e-09,-0.15828253,0.054834723
"Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein",0.0,1.0,0.0,-0.15828615,0.6072769
Biotin transport and metabolism,0.00023790143,2.0,0.00023790143,-0.018592399,0.15498036
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,2.2851636e-05,2.0,2.2851636e-05,-0.14486787,0.064451866
Butyrophilin (BTN) family interactions,9.468746e-07,2.0,9.468746e-07,-0.15773016,0.05523073
C6 deamination of adenosine,6.067879e-07,2.0,6.067879e-07,-0.15792985,0.055087563
CD209 (DC-SIGN) signaling,9.806084e-07,2.0,9.806084e-07,-0.15771036,0.05524493
CD22 mediated BCR regulation,1.750549e-07,2.0,1.750549e-07,-0.15818337,0.054905828
CD28 co-stimulation,3.0725045e-09,3.0,3.0725045e-09,-0.15828435,-0.49761128
CDK-mediated phosphorylation and removal of Cdc6,2.5844285e-05,2.0,2.5844285e-05,-0.1431106,0.06571168
CDO in myogenesis,0.000408999,2.0,0.000408999,0.08187468,0.2270065
CHL1 interactions,1.1596704e-07,2.0,1.1596704e-07,-0.15821806,0.054880958
CLEC7A (Dectin-1) signaling,6.719956e-07,4.0,6.719956e-07,-0.15789156,-1.0497743
COPI-mediated anterograde transport,5.155602e-06,2.0,5.155602e-06,-0.15525883,0.057002462
COPII-mediated vesicle transport,2.4556693e-05,2.0,2.4556693e-05,-0.14386666,0.06516965
COX reactions,1.0080383e-08,2.0,1.0080383e-08,-0.15828024,0.05483637
CREB3 factors activate genes,0.00012368905,2.0,0.00012368905,-0.08565696,0.10690092
CRMPs in Sema3A signaling,0.00015831654,2.0,0.00015831654,-0.065323986,0.12147789
CTLA4 inhibitory signaling,9.505767e-06,2.0,9.505767e-06,-0.15270445,0.05883373
Ca2+ activated K+ channels,1.1510086e-06,2.0,1.1510086e-06,-0.1576103,0.055316664
Ca2+ pathway,2.7738166e-05,2.0,2.7738166e-05,-0.14199853,0.066508934
CaM pathway,8.735277e-05,2.0,8.735277e-05,-0.10699333,0.091604605
Cap-dependent Translation Initiation,0.01197966,7.0,0.01197966,6.876071,2.3356292
Carboxyterminal post-translational modifications of tubulin,2.6062668e-05,2.0,2.6062668e-05,-0.14298238,0.0658036
Cargo concentration in the ER,6.1402204e-07,2.0,6.1402204e-07,-0.1579256,0.05509062
Cargo recognition for clathrin-mediated endocytosis,0.00026914862,2.0,0.00026914862,-0.0002443119,0.16813433
Carnitine synthesis,5.106449e-07,2.0,5.106449e-07,-0.1579863,0.055047102
Catecholamine biosynthesis,0.0,2.0,0.0,-0.15828615,0.054832134
Cation-coupled Chloride cotransporters,0.00064941304,2.0,0.00064941304,0.22304381,0.32821244
"Cell death signalling via NRAGE, NRIF and NADE",0.00032945492,4.0,0.00032945492,0.035167053,-0.91136813
Cellular hexose transport,5.9490844e-07,2.0,5.9490844e-07,-0.15793683,0.055082567
Ceramide signalling,1.6621989e-06,2.0,1.6621989e-06,-0.15731013,0.055531867
ChREBP activates metabolic gene expression,6.316292e-07,2.0,6.316292e-07,-0.15791526,0.05509803
Cholesterol biosynthesis,4.662248e-06,3.0,4.662248e-06,-0.15554851,-0.49564993
Choline catabolism,1.281864e-06,2.0,1.281864e-06,-0.15753345,0.05537176
Chondroitin sulfate/dermatan sulfate metabolism,5.2986557e-06,5.0,5.2986557e-06,-0.15517484,-1.6002713
Chylomicron assembly,7.1225172e-09,2.0,7.1225172e-09,-0.15828197,0.05483513
Chylomicron clearance,1.0023168e-06,2.0,1.0023168e-06,-0.1576976,0.055254072
Chylomicron remodeling,4.005812e-08,2.0,4.005812e-08,-0.15826264,0.054848988
Citric acid cycle (TCA cycle),4.6253704e-06,2.0,4.6253704e-06,-0.15557016,0.056779254
Class A/1 (Rhodopsin-like receptors),0.0001052422,10.0,1.052422e-05,-0.15210643,-4.320422
Class B/2 (Secretin family receptors),0.0004328336,3.0,0.0004328336,0.09587015,-0.31540468
Class C/3 (Metabotropic glutamate/pheromone receptors),4.93901e-06,2.0,4.93901e-06,-0.15538602,0.05691128
Classical Kir channels,8.39462e-06,2.0,8.39462e-06,-0.15335691,0.05836598
Clathrin derived vesicle budding,0.00033658085,3.0,0.00033658085,0.03935134,-0.35592374
Cleavage of Growing Transcript in the Termination Region ,6.52866e-09,2.0,6.52866e-09,-0.15828232,0.054834872
"Cobalamin (Cbl, vitamin B12) transport and metabolism",2.8763932e-06,2.0,2.8763932e-06,-0.15659717,0.056042988
Collagen chain trimerization,0.00034013507,2.0,0.00034013507,0.04143835,0.19801717
Collagen degradation,0.0010219541,2.0,0.0010219541,0.44179687,0.4850393
Common Pathway of Fibrin Clot Formation,4.2856205e-12,2.0,4.2856205e-12,-0.15828615,0.054832134
Constitutive Signaling by AKT1 E17K in Cancer,4.3121026e-06,2.0,4.3121026e-06,-0.15575412,0.056647375
Constitutive Signaling by Aberrant PI3K in Cancer,2.6685078e-07,2.0,2.6685078e-07,-0.15812947,0.054944467
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,0.0028851018,2.0,0.0028851018,1.5358218,1.2693596
Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0010328215,4.0,0.0010328215,0.44817808,-0.6152753
Creatine metabolism,7.826161e-06,2.0,7.826161e-06,-0.1536907,0.058126673
Cristae formation,8.6193216e-07,2.0,8.6193216e-07,-0.15778004,0.055194978
Crosslinking of collagen fibrils,4.1896674e-05,2.0,4.1896674e-05,-0.13368477,0.07246918
Cyclin A:Cdk2-associated events at S phase entry,1.9311465e-05,2.0,1.9311465e-05,-0.14694662,0.062961586
Cysteine formation from homocysteine,4.887445e-07,2.0,4.887445e-07,-0.15799917,0.055037875
Cytochrome P450 - arranged by substrate type,0.00016597056,7.0,0.00016597056,-0.060829613,-2.6375234
Cytosolic iron-sulfur cluster assembly,1.5933898e-05,2.0,1.5933898e-05,-0.1489299,0.061539747
Cytosolic sulfonation of small molecules,1.4688923e-05,2.0,1.4688923e-05,-0.14966093,0.061015658
Cytosolic tRNA aminoacylation,0.00023067072,2.0,0.00023067072,-0.022838216,0.15193649
DAP12 signaling,9.5963e-05,2.0,9.5963e-05,-0.10193747,0.09522922
DCC mediated attractive signaling,8.860961e-09,2.0,8.860961e-09,-0.15828095,0.054835856
DEx/H-box helicases activate type I IFN and inflammatory cytokines production ,4.0391854e-09,2.0,4.0391854e-09,-0.15828378,0.054833837
DNA Damage Recognition in GG-NER,0.00030518929,2.0,0.00030518929,0.020918472,0.1833062
DNA Damage/Telomere Stress Induced Senescence,0.00044437096,2.0,0.00044437096,0.1026448,0.24189687
DNA methylation,3.0777146e-06,2.0,3.0777146e-06,-0.15647896,0.056127734
DNA replication initiation,1.5059578e-06,2.0,1.5059578e-06,-0.15740187,0.05546609
DSCAM interactions,8.507067e-05,2.0,8.507067e-05,-0.10833336,0.09064393
Deactivation of the beta-catenin transactivating complex,1.897604e-05,2.0,1.897604e-05,-0.14714357,0.06282039
Deadenylation of mRNA,1.0131115e-07,2.0,1.0131115e-07,-0.15822667,0.054874778
Dectin-2 family,5.186263e-06,2.0,5.186263e-06,-0.15524082,0.057015367
Defective ABCA1 causes Tangier disease,0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCA12 causes autosomal recessive congenital ichthyosis type 4B,0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction 3 (SMDP3),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCB11 causes progressive familial intrahepatic cholestasis 2 and benign recurrent intrahepatic cholestasis 2,0.0,2.0,0.0,-0.15828615,0.054832134
"Defective ABCB4 causes progressive familial intrahepatic cholestasis 3, intrahepatic cholestasis of pregnancy 3 and gallbladder disease 1",0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCB6 causes isolated colobomatous microphthalmia 7 (MCOPCB7),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCC2 causes Dubin-Johnson syndrome,0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCC6 causes pseudoxanthoma elasticum (PXE),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCC8 can cause hypoglycemias and hyperglycemias,0.0,2.0,0.0,-0.15828615,0.054832134
"Defective ABCC9 causes dilated cardiomyopathy 10, familial atrial fibrillation 12 and hypertrichotic osteochondrodysplasia",0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCD1 causes adrenoleukodystrophy (ALD),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective ABCD4 causes methylmalonic aciduria and homocystinuria, cblj type (MAHCJ)",0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCG5 causes sitosterolemia,0.0,2.0,0.0,-0.15828615,0.054832134
Defective ABCG8 causes gallbladder disease 4 and sitosterolemia,0.0,2.0,0.0,-0.15828615,0.054832134
Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD),2.760771e-07,2.0,2.760771e-07,-0.15812404,0.05494835
Defective ACY1 causes encephalopathy,0.0,2.0,0.0,-0.15828615,0.054832134
Defective AHCY causes Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ALG1 causes ALG1-CDG (CDG-1k),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ALG11 causes ALG11-CDG (CDG-1p),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ALG12 causes ALG12-CDG (CDG-1g),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ALG2 causes ALG2-CDG (CDG-1i),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ALG3 causes ALG3-CDG (CDG-1d),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ALG6 causes ALG6-CDG (CDG-1c),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ALG8 causes ALG8-CDG (CDG-1h),0.0,2.0,0.0,-0.15828615,0.054832134
Defective ALG9 causes ALG9-CDG (CDG-1l),0.0,2.0,0.0,-0.15828615,0.054832134
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),6.242851e-08,2.0,6.242851e-08,-0.1582495,0.054858405
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),6.242851e-08,2.0,6.242851e-08,-0.1582495,0.054858405
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),1.2171361e-06,2.0,1.2171361e-06,-0.15757146,0.055344496
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),1.2171361e-06,2.0,1.2171361e-06,-0.15757146,0.055344496
Defective B3GALT6 causes EDSP2 and SEMDJL1,3.7699195e-07,2.0,3.7699195e-07,-0.1580648,0.054990828
Defective B3GALTL causes Peters-plus syndrome (PpS),1.2176241e-12,2.0,1.2176241e-12,-0.15828615,0.054832134
Defective B3GAT3 causes JDSSDHD,6.8938084e-07,2.0,6.8938084e-07,-0.15788135,0.055122335
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,2.0,0.0,-0.15828615,0.054832134
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,2.0,0.0,-0.15828615,0.054832134
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,2.0,0.0,-0.15828615,0.054832134
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective B4GALT7 causes EDS, progeroid type",8.1960806e-08,2.0,8.1960806e-08,-0.15823804,0.054866627
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),4.7661772e-09,2.0,4.7661772e-09,-0.15828335,0.054834135
Defective CFTR causes cystic fibrosis,0.00023804633,2.0,0.00023804633,-0.018507319,0.15504135
"Defective CHST14 causes EDS, musculocontractural type",1.9557807e-11,2.0,1.9557807e-11,-0.15828614,0.054832146
Defective CHST3 causes SEDCJD,3.0508968e-10,2.0,3.0508968e-10,-0.15828599,0.054832254
Defective CHST6 causes MCDC1,0.0,2.0,0.0,-0.15828615,0.054832134
Defective CHSY1 causes TPBS,6.4657485e-08,2.0,6.4657485e-08,-0.15824819,0.05485936
Defective CP causes aceruloplasminemia (ACERULOP),0.0,2.0,0.0,-0.15828615,0.054832134
Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4),2.2708811e-07,2.0,2.2708811e-07,-0.1581528,0.054927737
Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5),9.161389e-08,2.0,9.161389e-08,-0.15823236,0.054870702
"Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)",1.2347405e-06,2.0,1.2347405e-06,-0.15756114,0.055351906
Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4),0.0,2.0,0.0,-0.15828615,0.054832134
Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency),0.0,2.0,0.0,-0.15828615,0.054832134
Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5),0.0,2.0,0.0,-0.15828615,0.054832134
Defective CYP19A1 causes Aromatase excess syndrome (AEXS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective CYP1B1 causes Glaucoma,0.0,2.0,0.0,-0.15828615,0.054832134
Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)",0.0,2.0,0.0,-0.15828615,0.054832134
Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA),0.0,2.0,0.0,-0.15828615,0.054832134
Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4),0.0,2.0,0.0,-0.15828615,0.054832134
Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX),0.0,2.0,0.0,-0.15828615,0.054832134
Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A),0.0,2.0,0.0,-0.15828615,0.054832134
Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)",0.0,2.0,0.0,-0.15828615,0.054832134
"Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)",0.0,2.0,0.0,-0.15828615,0.054832134
"Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)",0.0,2.0,0.0,-0.15828615,0.054832134
Defective DHDDS causes retinitis pigmentosa 59,0.0,2.0,0.0,-0.15828615,0.054832134
Defective DOLK causes DOLK-CDG (CDG-1m),0.0,2.0,0.0,-0.15828615,0.054832134
Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2,0.0,2.0,0.0,-0.15828615,0.054832134
Defective DPM1 causes DPM1-CDG (CDG-1e),0.0,2.0,0.0,-0.15828615,0.054832134
Defective DPM2 causes DPM2-CDG (CDG-1u),0.0,2.0,0.0,-0.15828615,0.054832134
Defective DPM3 causes DPM3-CDG (CDG-1o),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective EXT1 causes exostoses 1, TRPS2 and CHDS",1.2222993e-08,2.0,1.2222993e-08,-0.15827897,0.05483728
Defective EXT2 causes exostoses 2,2.6702747e-07,2.0,2.6702747e-07,-0.15812936,0.05494454
Defective FMO3 causes Trimethylaminuria (TMAU),0.0,2.0,0.0,-0.15828615,0.054832134
Defective GALE can cause Epimerase-deficiency galactosemia (EDG),0.0,2.0,0.0,-0.15828615,0.054832134
Defective GALK1 can cause Galactosemia II (GALCT2),0.0,2.0,0.0,-0.15828615,0.054832134
Defective GALNT12 causes colorectal cancer 1 (CRCS1),9.496951e-08,2.0,9.496951e-08,-0.1582304,0.054872103
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),1.0862119e-07,2.0,1.0862119e-07,-0.15822238,0.054877855
Defective GALT can cause Galactosemia,0.0,2.0,0.0,-0.15828615,0.054832134
Defective GCK causes maturity-onset diabetes of the young 2 (MODY2),0.0,2.0,0.0,-0.15828615,0.054832134
Defective GCLC causes Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD),0.0,2.0,0.0,-0.15828615,0.054832134
Defective GFPT1 causes CMSTA1,0.0,2.0,0.0,-0.15828615,0.054832134
Defective GGT1 causes Glutathionuria (GLUTH),0.0,2.0,0.0,-0.15828615,0.054832134
Defective GGT1 causes Glutathionuria (GLUTH),0.0,2.0,0.0,-0.15828615,0.054832134
Defective GGT1 causes Glutathionuria (GLUTH),0.0,2.0,0.0,-0.15828615,0.054832134
Defective GGT1 causes Glutathionuria (GLUTH),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective GNE causes sialuria, Nonaka myopathy and inclusion body myopathy 2",0.0,2.0,0.0,-0.15828615,0.054832134
Defective GSS causes Glutathione synthetase deficiency (GSS deficiency),0.0,2.0,0.0,-0.15828615,0.054832134
Defective HEXA causes GM2G1,0.0,2.0,0.0,-0.15828615,0.054832134
Defective HEXB causes GM2G2,0.0,2.0,0.0,-0.15828615,0.054832134
Defective HK1 causes hexokinase deficiency (HK deficiency),0.0,2.0,0.0,-0.15828615,0.054832134
Defective LARGE causes MDDGA6 and MDDGB6,0.0,2.0,0.0,-0.15828615,0.054832134
Defective LFNG causes SCDO3,8.859658e-12,2.0,8.859658e-12,-0.15828615,0.054832134
Defective MAN1B1 causes MRT15,0.0,2.0,0.0,-0.15828615,0.054832134
Defective MAOA causes Brunner syndrome (BRUNS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective MAT1A causes Methionine adenosyltransferase deficiency (MATD),0.0,2.0,0.0,-0.15828615,0.054832134
Defective MGAT2 causes MGAT2-CDG (CDG-2a),0.0,2.0,0.0,-0.15828615,0.054832134
Defective MOGS causes MOGS-CDG (CDG-2b),0.0,2.0,0.0,-0.15828615,0.054832134
Defective MPDU1 causes MPDU1-CDG (CDG-1f),0.0,2.0,0.0,-0.15828615,0.054832134
Defective MPI causes MPI-CDG (CDG-1b),0.0,2.0,0.0,-0.15828615,0.054832134
Defective Mismatch Repair Associated With MLH1,5.246694e-06,2.0,5.246694e-06,-0.15520534,0.057040807
Defective Mismatch Repair Associated With MSH2,6.7563484e-09,2.0,6.7563484e-09,-0.15828219,0.05483497
Defective Mismatch Repair Associated With MSH3,7.957752e-06,2.0,7.957752e-06,-0.15361343,0.05818206
Defective Mismatch Repair Associated With MSH6,1.6553726e-08,2.0,1.6553726e-08,-0.15827644,0.05483911
Defective Mismatch Repair Associated With PMS2,1.1360335e-09,2.0,1.1360335e-09,-0.15828548,0.054832608
Defective NEU1 causes sialidosis,0.0,2.0,0.0,-0.15828615,0.054832134
Defective OPLAH causes 5-oxoprolinase deficiency (OPLAHD),0.0,2.0,0.0,-0.15828615,0.054832134
Defective PAPSS2 causes SEMD-PA,0.0,2.0,0.0,-0.15828615,0.054832134
Defective PGM1 causes PGM1-CDG (CDG1t),0.0,2.0,0.0,-0.15828615,0.054832134
Defective PMM2 causes PMM2-CDG (CDG-1a),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3",1.0452658e-10,2.0,1.0452658e-10,-0.15828608,0.05483218
"Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1",2.3275743e-12,2.0,2.3275743e-12,-0.15828615,0.054832134
"Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2",4.2634448e-14,2.0,4.2634448e-14,-0.15828615,0.054832134
Defective RFT1 causes RFT1-CDG (CDG-1n),0.0,2.0,0.0,-0.15828615,0.054832134
Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)",0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC12A1 causes Bartter syndrome 1 (BS1),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC12A3 causes Gitelman syndrome (GS),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN)",0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC17A5 causes Salla disease (SD) and ISSD,0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC1A3 causes episodic ataxia 6 (EA6),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC26A2 causes chondrodysplasias,0.0,3.0,0.0,-0.15828615,-0.49761257
Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC26A4 causes Pendred syndrome (PDS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC2A10 causes arterial tortuosity syndrome (ATS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC2A9 causes hypouricemia renal 2 (RHUC2),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC33A1 causes spastic paraplegia 42 (SPG42),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS)",0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC35D1 causes Schneckenbecken dysplasia (SCHBCKD),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ)",0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC3A1 causes cystinuria (CSNU),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0,2.0,0.0,-0.15828615,0.054832134
"Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)",0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC5A2 causes renal glucosuria (GLYS1),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A19 causes Hartnup disorder (HND),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A19 causes Hartnup disorder (HND),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A19 causes Hartnup disorder (HND),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A19 causes Hartnup disorder (HND),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A2 causes orthostatic intolerance (OI),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC6A5 causes hyperekplexia 3 (HKPX3),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC7A9 causes cystinuria (CSNU),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH)",0.0,2.0,0.0,-0.15828615,0.054832134
Defective SLC9A9 causes autism 16 (AUTS16),0.0,2.0,0.0,-0.15828615,0.054832134
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,2.0,0.0,-0.15828615,0.054832134
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,2.0,0.0,-0.15828615,0.054832134
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",5.167292e-06,2.0,5.167292e-06,-0.15525196,0.05700738
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",5.167292e-06,2.0,5.167292e-06,-0.15525196,0.05700738
"Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)",1.6478538e-07,2.0,1.6478538e-07,-0.1581894,0.054901496
"Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)",0.0,2.0,0.0,-0.15828615,0.054832134
Defective SRD5A3 causes SRD5A3-CDG (CDG-1q) and KHRZ,0.0,2.0,0.0,-0.15828615,0.054832134
Defective ST3GAL3 causes MCT12 and EIEE15,0.0,2.0,0.0,-0.15828615,0.054832134
Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD),0.0,2.0,0.0,-0.15828615,0.054832134
Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency),0.0,2.0,0.0,-0.15828615,0.054832134
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC),0.0,2.0,0.0,-0.15828615,0.054832134
Defective UGT1A1 causes hyperbilirubinemia,0.0,2.0,0.0,-0.15828615,0.054832134
Defective UGT1A4 causes hyperbilirubinemia,0.0,2.0,0.0,-0.15828615,0.054832134
Defective pro-SFTPB causes pulmonary surfactant metabolism dysfunction 1 (SMDP1) and respiratory distress syndrome (RDS),8.38988e-07,2.0,8.38988e-07,-0.15779352,0.05518531
Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS),1.709695e-08,2.0,1.709695e-08,-0.15827613,0.05483932
Defects in biotin (Btn) metabolism,5.074312e-06,3.0,5.074312e-06,-0.15530656,-0.49547645
Defects in cobalamin (B12) metabolism,6.631058e-07,15.0,4.4207056e-08,-0.1582602,-7.1266694
Defensins,1.4658913e-06,3.0,1.4658913e-06,-0.15742539,-0.49699548
Degradation of AXIN,3.945482e-05,2.0,3.945482e-05,-0.13511862,0.07144123
Degradation of DVL,0.0032197114,2.0,0.0032197114,1.7323018,1.4102185
Degradation of GLI1 by the proteasome,2.7189719e-05,2.0,2.7189719e-05,-0.14232057,0.066278055
Degradation of GLI2 by the proteasome,0.00043009326,2.0,0.00043009326,0.09426106,0.23588644
Degradation of cysteine and homocysteine,3.5692278e-07,2.0,3.5692278e-07,-0.15807657,0.054982383
Deposition of new CENPA-containing nucleosomes at the centromere,0.007901548,2.0,0.007901548,4.4814377,3.3811095
Depurination,5.5987975e-10,3.0,5.5987975e-10,-0.15828583,-0.49761236
Depyrimidination,0.00016478135,3.0,0.00016478135,-0.061527908,-0.42824534
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,2.0035144e-05,2.0,2.0035144e-05,-0.14652169,0.06326623
Detoxification of Reactive Oxygen Species,6.366441e-05,2.0,6.366441e-05,-0.12090294,0.08163264
Digestion of dietary carbohydrate,0.0046963794,2.0,0.0046963794,2.599389,2.0318446
Digestion of dietary lipid,2.3698776e-05,2.0,2.3698776e-05,-0.14437042,0.064808495
Disassembly of the destruction complex and recruitment of AXIN to the membrane,0.0005134162,2.0,0.0005134162,0.1431876,0.2709625
Disinhibition of SNARE formation,5.3376702e-06,2.0,5.3376702e-06,-0.15515192,0.057079107
Displacement of DNA glycosylase by APEX1,4.5116103e-05,2.0,4.5116103e-05,-0.13179435,0.07382444
Dissolution of Fibrin Clot,1.0702645e-06,2.0,1.0702645e-06,-0.1576577,0.055282675
Dopamine Neurotransmitter Release Cycle,2.940298e-07,2.0,2.940298e-07,-0.1581135,0.054955907
Dopamine clearance from the synaptic cleft,5.526928e-09,3.0,5.526928e-09,-0.1582829,-0.49761024
Downregulation of ERBB2 signaling,0.00042150763,2.0,0.00042150763,0.089219645,0.2322722
Downregulation of ERBB4 signaling,3.7743548e-06,2.0,3.7743548e-06,-0.15606989,0.056421008
Downstream TCR signaling,1.7669576e-06,2.0,1.7669576e-06,-0.15724862,0.05557596
Downstream signal transduction,2.4532392e-06,2.0,2.4532392e-06,-0.15684563,0.055864863
Downstream signaling events of B Cell Receptor (BCR),7.715552e-06,4.0,7.715552e-06,-0.15375565,-1.0468092
Dual Incision in GG-NER,1.268427e-05,2.0,1.268427e-05,-0.15083806,0.060171764
Dual incision in TC-NER,0.0060367477,2.0,0.0060367477,3.3864422,2.5960932
E3 ubiquitin ligases ubiquitinate target proteins,0.00041671953,2.0,0.00041671953,0.08640811,0.23025657
ECM proteoglycans,1.625729e-05,2.0,1.625729e-05,-0.14874001,0.06167588
EGFR downregulation,0.00016130786,2.0,0.00016130786,-0.06356751,0.12273713
EGFR interacts with phospholipase C-gamma,2.320482e-06,2.0,2.320482e-06,-0.15692359,0.055808976
EPH-ephrin mediated repulsion of cells,1.6536316e-06,2.0,1.6536316e-06,-0.15731516,0.055528253
EPHA-mediated growth cone collapse,1.9954414e-05,2.0,1.9954414e-05,-0.1465691,0.06323224
EPHB-mediated forward signaling,2.8600349e-05,2.0,2.8600349e-05,-0.14149226,0.06687188
ERBB2 Activates PTK6 Signaling,0.0035966302,3.0,0.0035966302,1.9536254,1.0164437
ERBB2 Regulates Cell Motility,1.3820336e-05,2.0,1.3820336e-05,-0.15017097,0.060650006
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,4.0681294e-07,2.0,4.0681294e-07,-0.15804727,0.055003382
Electric Transmission Across Gap Junctions,1.4028132e-07,2.0,1.4028132e-07,-0.15820378,0.054891188
Electron transport from NADPH to Ferredoxin,1.5119674e-05,2.0,1.5119674e-05,-0.14940801,0.061196987
Elevation of cytosolic Ca2+ levels,1.2473623e-06,2.0,1.2473623e-06,-0.15755372,0.05535723
Endosomal Sorting Complex Required For Transport (ESCRT),0.00017862064,2.0,0.00017862064,-0.05340159,0.13002521
Energy dependent regulation of mTOR by LKB1-AMPK,1.849499e-05,2.0,1.849499e-05,-0.14742605,0.062617876
Ephrin signaling,1.9335637e-05,2.0,1.9335637e-05,-0.14693244,0.062971756
Erythrocytes take up carbon dioxide and release oxygen,0.0012560039,2.0,0.0012560039,0.57922894,0.58356607
Erythrocytes take up oxygen and release carbon dioxide,0.00030746983,2.0,0.00030746983,0.02225759,0.18426624
Essential fructosuria,0.0,2.0,0.0,-0.15828615,0.054832134
Essential pentosuria,0.0,2.0,0.0,-0.15828615,0.054832134
Establishment of Sister Chromatid Cohesion,4.2394986e-06,2.0,4.2394986e-06,-0.15579675,0.056616817
Estrogen-dependent gene expression,0.000121487064,2.0,0.000121487064,-0.08694995,0.10597396
Ethanol oxidation,1.750642e-07,2.0,1.750642e-07,-0.15818337,0.054905828
Eukaryotic Translation Termination,3.3152995e-05,2.0,3.3152995e-05,-0.138819,0.06878839
Expression and Processing of Neurotrophins,0.00023345403,2.0,0.00023345403,-0.021203876,0.15310816
Extension of Telomeres,0.0011483779,3.0,0.0011483779,0.51603186,-0.014185406
Extrinsic Pathway of Fibrin Clot Formation,2.1948779e-06,2.0,2.1948779e-06,-0.15699735,0.055756092
FBXW7 Mutants and NOTCH1 in Cancer,6.811773e-07,2.0,6.811773e-07,-0.15788618,0.05511888
FCERI mediated Ca+2 mobilization,2.1157957e-05,2.0,2.1157957e-05,-0.14586237,0.063738905
FCERI mediated MAPK activation,3.8186236e-06,2.0,3.8186236e-06,-0.15604389,0.056439634
FCERI mediated NF-kB activation,0.00024937157,2.0,0.00024937157,-0.011857227,0.15980889
FCGR activation,3.6661152e-07,2.0,3.6661152e-07,-0.15807088,0.054986466
FMO oxidises nucleophiles,2.0929498e-07,2.0,2.0929498e-07,-0.15816326,0.05492023
Fanconi Anemia Pathway,0.009186473,2.0,0.009186473,5.2359347,3.922018
FasL/ CD95L signaling,0.00010224632,2.0,0.00010224632,-0.09824796,0.097874284
Fatty acyl-CoA biosynthesis,2.3694965e-06,2.0,2.3694965e-06,-0.15689482,0.055829603
Fibronectin matrix formation,0.0,2.0,0.0,-0.15828615,0.054832134
Formation of ATP by chemiosmotic coupling,0.0,2.0,0.0,-0.15828615,0.054832134
Formation of Incision Complex in GG-NER,2.6144318e-05,2.0,2.6144318e-05,-0.14293443,0.06583798
Formation of RNA Pol II elongation complex ,1.0819712e-06,2.0,1.0819712e-06,-0.15765083,0.055287603
Formation of TC-NER Pre-Incision Complex,0.022759233,2.0,0.022759233,13.205748,9.635678
Formation of editosomes by ADAR proteins,7.36898e-08,2.0,7.36898e-08,-0.15824288,0.054863155
Formation of selenosugars for excretion,0.0,2.0,0.0,-0.15828615,0.054832134
Formation of the Early Elongation Complex,1.4936973e-09,2.0,1.4936973e-09,-0.15828529,0.054832757
Formation of the Editosome,1.8731862e-05,2.0,1.8731862e-05,-0.14728695,0.062717594
Formation of the beta-catenin:TCF transactivating complex,3.1582456e-06,2.0,3.1582456e-06,-0.15643167,0.05616164
Formation of the cornified envelope,1.3631611e-06,2.0,1.3631611e-06,-0.15748572,0.055405974
Formation of xylulose-5-phosphate,1.0049203e-05,2.0,1.0049203e-05,-0.15238534,0.0590625
Free fatty acids regulate insulin secretion,2.2190559e-08,2.0,2.2190559e-08,-0.15827313,0.05484147
Fructose biosynthesis,2.2055566e-09,2.0,2.2055566e-09,-0.15828486,0.054833066
Fructose catabolism,1.296512e-05,2.0,1.296512e-05,-0.15067315,0.060289998
G alpha (12/13) signalling events,0.0011391485,2.0,0.0011391485,0.5106124,0.53437406
G alpha (i) signalling events,0.00032147235,2.0,0.00032147235,0.030479755,0.19016081
G alpha (q) signalling events,0.0011818012,2.0,0.0011818012,0.53565776,0.55232936
G alpha (s) signalling events,4.837856e-05,2.0,4.837856e-05,-0.12987867,0.07519782
G alpha (z) signalling events,0.0004854778,2.0,0.0004854778,0.1267824,0.2592014
G protein gated Potassium channels,2.7454505e-05,2.0,2.7454505e-05,-0.1421651,0.06638952
G-protein beta:gamma signalling,0.0027148281,3.0,0.0027148281,1.4358385,0.64523566
G0 and Early G1,0.0025154864,3.0,0.0025154864,1.3187866,0.5613197
G1 Phase,1.5107105e-05,2.0,1.5107105e-05,-0.14941539,0.061191697
G1/S Transition,2.3975792e-05,4.0,2.3975792e-05,-0.14420776,-1.0399643
G2 Phase,6.812629e-08,2.0,6.812629e-08,-0.15824614,0.05486081
G2/M DNA damage checkpoint,1.4808022e-07,2.0,1.4808022e-07,-0.1581992,0.05489447
G2/M DNA replication checkpoint,2.6799514e-08,2.0,2.6799514e-08,-0.15827042,0.054843415
G2/M Transition,0.0003366869,9.0,3.7409656e-05,-0.13631952,-3.6705472
GAB1 signalosome,0.0003198645,2.0,0.0003198645,0.029535646,0.18948399
GABA receptor activation,4.0134026e-05,4.0,4.0134026e-05,-0.13471979,-1.0331622
"GABA synthesis, release, reuptake and degradation",1.0565972e-05,4.0,1.0565972e-05,-0.1520819,-1.0456094
GLI proteins bind promoters of Hh responsive genes to promote transcription,7.5012963e-06,2.0,7.5012963e-06,-0.15388145,0.05798992
GLI3 is processed to GLI3R by the proteasome,2.6148055e-06,2.0,2.6148055e-06,-0.15675077,0.05593288
GP1b-IX-V activation signalling,6.867959e-05,2.0,6.867959e-05,-0.11795806,0.083743855
GPVI-mediated activation cascade,2.6537122e-05,2.0,2.6537122e-05,-0.14270377,0.066003345
GRB2 events in EGFR signaling,1.5707243e-05,2.0,1.5707243e-05,-0.14906299,0.061444342
GRB2 events in ERBB2 signaling,0.00053795526,2.0,0.00053795526,0.15759672,0.2812926
GRB2:SOS provides linkage to MAPK signaling for Integrins ,4.3074183e-06,2.0,4.3074183e-06,-0.15575688,0.05664541
GRB7 events in ERBB2 signaling,2.245009e-05,2.0,2.245009e-05,-0.14510365,0.064282835
Galactose catabolism,6.930056e-06,2.0,6.930056e-06,-0.15421689,0.057749443
"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",5.8078065e-08,4.0,5.8078065e-08,-0.15825205,-1.0500329
Gap junction trafficking,8.97362e-05,3.0,8.97362e-05,-0.10559381,-0.45983678
Gap-filling DNA repair synthesis and ligation in GG-NER,1.7083166e-05,2.0,1.7083166e-05,-0.14825507,0.06202355
Gap-filling DNA repair synthesis and ligation in TC-NER,1.9370966e-05,2.0,1.9370966e-05,-0.1469117,0.06298663
Generation of second messenger molecules,4.762549e-07,2.0,4.762549e-07,-0.1580065,0.055032615
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,5.7375075e-07,2.0,5.7375075e-07,-0.15794925,0.055073664
Gluconeogenesis,4.027438e-06,2.0,4.027438e-06,-0.15592127,0.056527548
Glucuronidation,0.0,2.0,0.0,-0.15828615,0.054832134
Glutamate Neurotransmitter Release Cycle,2.569574e-06,2.0,2.569574e-06,-0.15677732,0.055913836
"Glutamate binding, activation of AMPA receptors and synaptic plasticity",3.0613996e-09,3.0,3.0613996e-09,-0.15828437,-0.49761128
Glutathione conjugation,4.1924827e-06,2.0,4.1924827e-06,-0.15582436,0.056597024
Glycerophospholipid biosynthesis,4.2369475e-06,19.0,2.2299723e-07,-0.15815522,-9.334945
Glycine degradation,2.4374705e-05,2.0,2.4374705e-05,-0.14397354,0.06509304
Glycogen breakdown (glycogenolysis),9.750282e-06,2.0,9.750282e-06,-0.15256087,0.058936663
Glycogen storage diseases,3.226641e-08,10.0,3.226641e-09,-0.15828426,-4.364712
Glycogen synthesis,6.0086495e-05,2.0,6.0086495e-05,-0.12300386,0.08012645
Glycolysis,1.0708833e-06,2.0,1.0708833e-06,-0.15765734,0.05528293
Glycoprotein hormones,0.0,2.0,0.0,-0.15828615,0.054832134
Glycosphingolipid metabolism,5.513709e-07,2.0,5.513709e-07,-0.1579624,0.055064242
Golgi-to-ER retrograde transport,2.3178315e-07,3.0,2.3178315e-07,-0.15815005,-0.497515
Growth hormone receptor signaling,8.559607e-07,2.0,8.559607e-07,-0.15778354,0.055192463
HATs acetylate histones,5.666319e-05,2.0,5.666319e-05,-0.12501399,0.07868537
HCN channels,5.8534692e-06,2.0,5.8534692e-06,-0.15484904,0.057296243
HDACs deacetylate histones,0.00062714826,2.0,0.00062714826,0.20997012,0.31883973
HDL assembly,1.0433388e-06,2.0,1.0433388e-06,-0.15767351,0.05527134
HDL clearance,1.0018183e-05,2.0,1.0018183e-05,-0.15240356,0.059049435
HDL remodeling,4.8664874e-06,2.0,4.8664874e-06,-0.1554286,0.056880753
HDMs demethylate histones,1.6255848e-07,2.0,1.6255848e-07,-0.15819071,0.054900557
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),3.3820703e-05,4.0,3.3820703e-05,-0.13842691,-1.0358199
HDR through MMEJ (alt-NHEJ),0.0006130363,2.0,0.0006130363,0.20168369,0.31289908
HHAT G278V abrogates palmitoylation of Hh-Np,0.0,2.0,0.0,-0.15828615,0.054832134
HIV Life Cycle,0.00288962,3.0,0.00288962,1.5384748,0.7188169
HSF1 activation,3.702487e-05,2.0,3.702487e-05,-0.13654545,0.07041832
HSF1-dependent transactivation,1.3049e-06,2.0,1.3049e-06,-0.15751994,0.055381447
HSP90 chaperone cycle for steroid hormone receptors (SHR),2.1703367e-05,2.0,2.1703367e-05,-0.14554211,0.063968495
Heme biosynthesis,0.00027637242,2.0,0.00027637242,0.003997446,0.17117532
Heme degradation,2.8342813e-05,2.0,2.8342813e-05,-0.1416435,0.066763476
Heparan sulfate/heparin (HS-GAG) metabolism,2.3251243e-05,4.0,2.3251243e-05,-0.14463322,-1.0402694
Hereditary fructose intolerance,0.0,2.0,0.0,-0.15828615,0.054832134
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD,1.6880404e-05,2.0,1.6880404e-05,-0.14837413,0.061938193
Histidine catabolism,7.7130025e-08,2.0,7.7130025e-08,-0.15824087,0.054864597
Host Interactions of HIV factors,0.00011654256,8.0,0.00011654256,-0.089853324,-3.2107756
Host Interactions with Influenza Factors,7.540406e-07,3.0,7.540406e-07,-0.15784338,-0.49729517
HuR (ELAVL1) binds and stabilizes mRNA,6.462527e-05,2.0,6.462527e-05,-0.12033874,0.08203712
Hyaluronan metabolism,6.6710605e-08,3.0,6.6710605e-08,-0.15824698,-0.4975845
Hypusine synthesis from eIF5A-lysine,6.982113e-07,2.0,6.982113e-07,-0.15787618,0.055126052
IGF1R signaling cascade,7.157471e-06,2.0,7.157471e-06,-0.15408334,0.057845183
IKBKB deficiency causes SCID,2.2358716e-07,2.0,2.2358716e-07,-0.15815488,0.05492625
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR),2.5494385e-06,2.0,2.5494385e-06,-0.15678915,0.055905357
IP3 and IP4 transport between cytosol and nucleus,0.0,2.0,0.0,-0.15828615,0.054832134
IP6 and IP7 transport between cytosol and nucleus,0.0,2.0,0.0,-0.15828615,0.054832134
IPs transport between ER lumen and cytosol,0.0,2.0,0.0,-0.15828615,0.054832134
IPs transport between ER lumen and nucleus,0.0,2.0,0.0,-0.15828615,0.054832134
IPs transport between cytosol and ER lumen,0.0,2.0,0.0,-0.15828615,0.054832134
IPs transport between nucleus and ER lumen,0.0,2.0,0.0,-0.15828615,0.054832134
IPs transport between nucleus and cytosol,0.0,2.0,0.0,-0.15828615,0.054832134
IRAK4 deficiency (TLR2/4),0.0001285287,2.0,0.0001285287,-0.08281516,0.10893825
IRAK4 deficiency (TLR5),2.140021e-06,2.0,2.140021e-06,-0.15702954,0.05573301
IkBA variant leads to EDA-ID,0.0010095078,2.0,0.0010095078,0.43448848,0.47979984
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,1.2069126e-05,2.0,1.2069126e-05,-0.15119927,0.05991281
Import of palmitoyl-CoA into the mitochondrial matrix,1.2909482e-05,2.0,1.2909482e-05,-0.15070581,0.060266573
Inactivation of CDC42 and RAC1,1.4650884e-09,2.0,1.4650884e-09,-0.1582853,0.054832745
Inflammasomes,2.5851562e-06,5.0,2.5851562e-06,-0.15676817,-1.6014136
Influenza Life Cycle,2.7863181e-05,7.0,2.7863181e-05,-0.14192513,-2.695662
Inhibition of TSC complex formation by PKB,1.0946398e-08,2.0,1.0946398e-08,-0.15827973,0.054836735
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components,4.5261724e-05,2.0,4.5261724e-05,-0.13170885,0.07388574
Initial triggering of complement,6.9868644e-09,3.0,6.9868644e-09,-0.15828206,-0.49760965
InlA-mediated entry of Listeria monocytogenes into host cells,3.7077432e-05,2.0,3.7077432e-05,-0.13651459,0.07044044
InlB-mediated entry of Listeria monocytogenes into host cell,7.5494415e-07,2.0,7.5494415e-07,-0.15784286,0.05514994
Inositol transporters,1.3325258e-08,2.0,1.3325258e-08,-0.15827833,0.054837737
Insulin effects increased synthesis of Xylulose-5-Phosphate,4.544877e-05,2.0,4.544877e-05,-0.13159901,0.07396449
Insulin processing,2.4619061e-05,2.0,2.4619061e-05,-0.14383006,0.06519591
Insulin receptor recycling,0.00041936385,2.0,0.00041936385,0.08796083,0.23136973
Insulin receptor signalling cascade,4.7439873e-05,4.0,4.7439873e-05,-0.13042985,-1.0300868
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA,5.4930787e-08,2.0,5.4930787e-08,-0.15825391,0.054855254
Integrin cell surface interactions,0.00010424267,2.0,0.00010424267,-0.097075716,0.09871467
Interaction With Cumulus Cells,0.0,2.0,0.0,-0.15828615,0.054832134
Interaction With The Zona Pellucida,2.5117597e-10,2.0,2.5117597e-10,-0.158286,0.054832242
Interaction between L1 and Ankyrins,2.546649e-08,2.0,2.546649e-08,-0.15827121,0.05484285
Interconversion of 2-oxoglutarate and 2-hydroxyglutarate,2.3524206e-05,2.0,2.3524206e-05,-0.14447293,0.06473501
Interconversion of nucleotide di- and triphosphates,0.00084193755,2.0,0.00084193755,0.33609262,0.40925854
Interconversion of polyamines,0.0,2.0,0.0,-0.15828615,0.054832134
Interferon alpha/beta signaling,2.5992314e-05,2.0,2.5992314e-05,-0.14302368,0.065773994
Interferon gamma signaling,1.8120583e-05,2.0,1.8120583e-05,-0.1476459,0.062460274
Interleukin-1 family signaling,2.4667395e-06,7.0,2.4667395e-06,-0.1568377,-2.706353
Interleukin-10 signaling,1.6264993e-08,2.0,1.6264993e-08,-0.1582766,0.054838978
Interleukin-12 family signaling,4.9839546e-05,5.0,4.9839546e-05,-0.12902078,-1.5815212
Interleukin-17 signaling,9.417628e-06,2.0,9.417628e-06,-0.1527562,0.058796618
Interleukin-2 family signaling,0.00055025326,6.0,0.00055025326,0.16481802,-1.9233091
Interleukin-20 family signaling,2.3647647e-06,2.0,2.3647647e-06,-0.15689757,0.055827625
"Interleukin-3, Interleukin-5 and GM-CSF signaling",4.516435e-06,3.0,4.516435e-06,-0.15563414,-0.4957113
Interleukin-4 and Interleukin-13 signaling,0.00044977537,2.0,0.00044977537,0.10581823,0.24417193
Interleukin-6 family signaling,7.2233875e-06,3.0,7.2233875e-06,-0.15404464,-0.49457178
Interleukin-7 signaling,8.713452e-05,2.0,8.713452e-05,-0.10712149,0.09151274
Intestinal hexose absorption,0.0,2.0,0.0,-0.15828615,0.054832134
Intestinal infectious diseases,0.0,2.0,0.0,-0.15828615,0.054832134
Intestinal lipid absorption,0.0,2.0,0.0,-0.15828615,0.054832134
Intestinal saccharidase deficiencies,0.0,2.0,0.0,-0.15828615,0.054832134
Intra-Golgi traffic,0.009828469,2.0,0.009828469,5.6129093,4.192276
Intracellular oxygen transport,0.0,2.0,0.0,-0.15828615,0.054832134
Intraflagellar transport,0.00024372233,2.0,0.00024372233,-0.015174417,0.15743075
Intrinsic Pathway of Fibrin Clot Formation,0.00014023152,2.0,0.00014023152,-0.075943366,0.11386473
Invadopodia formation,6.434075e-06,2.0,6.434075e-06,-0.15450813,0.057540655
Ion homeostasis,3.4576697e-05,2.0,3.4576697e-05,-0.13798301,0.06938772
Ion influx/efflux at host-pathogen interface,1.0009527e-06,2.0,1.0009527e-06,-0.15769841,0.055253495
Ion transport by P-type ATPases,9.351745e-05,2.0,9.351745e-05,-0.10337348,0.094199724
Josephin domain DUBs,0.00014125957,2.0,0.00014125957,-0.0753397,0.11429751
KSRP (KHSRP) binds and destabilizes mRNA,8.783132e-06,2.0,8.783132e-06,-0.15312877,0.058529526
Keratan sulfate/keratin metabolism,5.283922e-06,3.0,5.283922e-06,-0.15518348,-0.49538824
Kinesins,5.2402106e-06,2.0,5.2402106e-06,-0.15520915,0.05703808
L13a-mediated translational silencing of Ceruloplasmin expression,0.00012361543,2.0,0.00012361543,-0.08570019,0.10686992
LDL clearance,5.889051e-06,2.0,5.889051e-06,-0.15482816,0.05731121
LDL remodeling,0.0,2.0,0.0,-0.15828615,0.054832134
LGI-ADAM interactions,1.0627301e-08,2.0,1.0627301e-08,-0.15827991,0.054836605
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,1.20912e-07,2.0,1.20912e-07,-0.15821515,0.05488304
Lactose synthesis,1.2926468e-07,2.0,1.2926468e-07,-0.15821025,0.05488655
Lagging Strand Synthesis,8.4613675e-05,3.0,8.4613675e-05,-0.1086017,-0.46199316
Laminin interactions,2.1914963e-07,2.0,2.1914963e-07,-0.15815747,0.054924387
Leading Strand Synthesis,1.1573931e-05,2.0,1.1573931e-05,-0.15149005,0.059704356
Ligand-receptor interactions,0.0,2.0,0.0,-0.15828615,0.054832134
Lipid particle organization,3.6732774e-07,2.0,3.6732774e-07,-0.15807047,0.054986756
Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.0,2.0,0.0,-0.15828615,0.054832134
Loss of Function of SMAD2/3 in Cancer,2.910134e-05,3.0,2.910134e-05,-0.14119808,-0.48536193
Loss of Function of SMAD4 in Cancer,2.0925448e-09,2.0,2.0925448e-09,-0.15828493,0.054833014
Loss of Function of TGFBR1 in Cancer,0.00014836497,3.0,0.00014836497,-0.07116747,-0.43515608
Loss of Function of TGFBR2 in Cancer,3.7428595e-06,3.0,3.7428595e-06,-0.15608837,-0.49603695
Lysine catabolism,4.5148803e-07,2.0,4.5148803e-07,-0.15802105,0.05502219
Lysosomal oligosaccharide catabolism,7.768964e-07,2.0,7.768964e-07,-0.15782997,0.055159178
MAPK6/MAPK4 signaling,0.002247415,2.0,0.002247415,1.1613773,1.0009156
MET Receptor Activation,1.728412e-05,2.0,1.728412e-05,-0.14813706,0.062108148
MET activates PI3K/AKT signaling,1.7017783e-06,2.0,1.7017783e-06,-0.15728688,0.055548526
MET activates PTPN11,3.3979982e-06,2.0,3.3979982e-06,-0.15629089,0.05626256
MET activates RAS signaling,9.321755e-06,2.0,9.321755e-06,-0.1528125,0.058756266
MET activates STAT3,1.8629925e-07,2.0,1.8629925e-07,-0.15817676,0.05491055
MET promotes cell motility,1.6060372e-05,4.0,1.6060372e-05,-0.14885564,-1.0432963
MET receptor recycling,2.92833e-05,2.0,2.92833e-05,-0.14109124,0.067159384
MGMT-mediated DNA damage reversal,8.800064e-07,2.0,8.800064e-07,-0.15776943,0.05520259
MHC class II antigen presentation,3.797127e-05,2.0,3.797127e-05,-0.13598974,0.07081672
MTF1 activates gene expression,4.0004754e-05,2.0,4.0004754e-05,-0.1347957,0.07167274
Macroautophagy,1.7031016e-06,2.0,1.7031016e-06,-0.15728611,0.05554908
Major pathway of rRNA processing in the nucleolus and cytosol,6.35898e-08,2.0,6.35898e-08,-0.15824881,0.054858897
Meiotic recombination,7.66501e-05,2.0,7.66501e-05,-0.113277845,0.08709916
Meiotic synapsis,4.6202803e-08,2.0,4.6202803e-08,-0.15825902,0.054851584
Melanin biosynthesis,0.0,2.0,0.0,-0.15828615,0.054832134
Metabolism of Angiotensinogen to Angiotensins,3.6933503e-05,2.0,3.6933503e-05,-0.13659911,0.070379846
Metabolism of folate and pterines,6.920732e-06,2.0,6.920732e-06,-0.15422235,0.05774553
Metabolism of ingested H2SeO4 and H2SeO3 into H2Se,1.5676949e-07,2.0,1.5676949e-07,-0.1581941,0.054898128
Metabolism of ingested MeSeO2H into MeSeH,2.0659854e-07,2.0,2.0659854e-07,-0.15816484,0.054919105
"Metabolism of ingested SeMet, Sec, MeSec into H2Se",2.8125942e-05,2.0,2.8125942e-05,-0.14177084,0.066672176
Metabolism of steroid hormones,5.0805766e-06,6.0,5.0805766e-06,-0.15530288,-2.152808
Metabolism of vitamin K,1.2564024e-07,2.0,1.2564024e-07,-0.15821238,0.05488502
Metal ion SLC transporters,2.0940168e-05,2.0,2.0940168e-05,-0.14599025,0.06364722
Metal sequestration by antimicrobial proteins,0.0,2.0,0.0,-0.15828615,0.054832134
Metalloprotease DUBs,0.0010017923,2.0,0.0010017923,0.429958,0.47655183
Metallothioneins bind metals,0.0,2.0,0.0,-0.15828615,0.054832134
Methionine salvage pathway,2.1775274e-06,3.0,2.1775274e-06,-0.15700753,-0.49669594
Methylation,1.7672202e-05,2.0,1.7672202e-05,-0.1479092,0.062271513
Methylation of MeSeH for excretion,0.0,2.0,0.0,-0.15828615,0.054832134
MicroRNA (miRNA) biogenesis,2.5346258e-09,2.0,2.5346258e-09,-0.15828466,0.054833192
Miscellaneous transport and binding events,8.3590194e-08,2.0,8.3590194e-08,-0.15823707,0.054867312
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta),6.1176394e-07,2.0,6.1176394e-07,-0.15792693,0.055089656
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha),1.2477739e-06,2.0,1.2477739e-06,-0.15755348,0.0553574
Misspliced GSK3beta mutants stabilize beta-catenin,2.3270626e-05,2.0,2.3270626e-05,-0.14462183,0.06462826
Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling,9.598807e-08,2.0,9.598807e-08,-0.1582298,0.054872543
Mitochondrial ABC transporters,1.9684428e-05,2.0,1.9684428e-05,-0.14672762,0.06311859
Mitochondrial Fatty Acid Beta-Oxidation,5.2451082e-06,4.0,5.2451082e-06,-0.15520626,-1.0478492
Mitochondrial Uncoupling Proteins,0.0,3.0,0.0,-0.15828615,-0.49761257
Mitochondrial protein import,1.3054951e-05,2.0,1.3054951e-05,-0.15062039,0.060327817
Mitochondrial tRNA aminoacylation,0.0005316504,2.0,0.0005316504,0.15389456,0.27863845
Mitochondrial transcription initiation,6.718893e-09,2.0,6.718893e-09,-0.1582822,0.05483496
Mitochondrial transcription termination,6.7727336e-07,2.0,6.7727336e-07,-0.15788847,0.055117242
Mitochondrial translation elongation,1.9410312e-05,2.0,1.9410312e-05,-0.14688858,0.06300319
Mitochondrial translation initiation,1.0744339e-05,2.0,1.0744339e-05,-0.15197717,0.059355125
Mitochondrial translation termination,7.844097e-05,2.0,7.844097e-05,-0.11222627,0.087853044
Mitotic Metaphase and Anaphase,0.0005433471,3.0,0.0005433471,0.16076277,-0.26888233
Mitotic Prometaphase,0.00018008775,4.0,0.00018008775,-0.052540116,-0.97424656
Mitotic Prophase,0.00056660123,5.0,0.00056660123,0.1744174,-1.3639827
Mitotic Telophase/Cytokinesis,3.4564089e-06,2.0,3.4564089e-06,-0.15625659,0.056287155
Molecules associated with elastic fibres,2.3262759e-05,2.0,2.3262759e-05,-0.14462645,0.06462494
Molybdenum cofactor biosynthesis,3.0688578e-05,2.0,3.0688578e-05,-0.14026608,0.06775095
Mucopolysaccharidoses,0.0,12.0,0.0,-0.15828615,-5.4696145
Multifunctional anion exchangers,9.17294e-09,2.0,9.17294e-09,-0.15828077,0.054835994
MyD88 deficiency (TLR2/4),5.9586826e-05,2.0,5.9586826e-05,-0.12329726,0.07991612
MyD88 deficiency (TLR5),2.2802256e-05,2.0,2.2802256e-05,-0.14489685,0.06443109
N-glycan trimming in the ER and Calnexin/Calreticulin cycle,1.4433087e-06,2.0,1.4433087e-06,-0.15743865,0.05543972
NADPH regeneration,3.0127588e-08,2.0,3.0127588e-08,-0.15826847,0.054844815
NCAM1 interactions,2.4385442e-06,2.0,2.4385442e-06,-0.15685426,0.055858675
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,4.4825036e-05,2.0,4.4825036e-05,-0.13196526,0.07370191
NFG and proNGF binds to p75NTR,8.6003027e-10,2.0,8.6003027e-10,-0.15828565,0.0548325
NIK-->noncanonical NF-kB signaling,4.3224303e-05,2.0,4.3224303e-05,-0.1329052,0.073028065
NOD1/2 Signaling Pathway,2.0731563e-06,2.0,2.0731563e-06,-0.15706882,0.055704854
NOSIP mediated eNOS trafficking,0.0,2.0,0.0,-0.15828615,0.054832134
NOSTRIN mediated eNOS trafficking,7.083362e-07,2.0,7.083362e-07,-0.15787023,0.05513031
NOTCH1 Intracellular Domain Regulates Transcription,0.0001489549,2.0,0.0001489549,-0.07082107,0.11753697
NOTCH2 Activation and Transmission of Signal to the Nucleus,0.00239829,2.0,0.00239829,1.24997,1.0644288
NOTCH2 intracellular domain regulates transcription,8.52478e-06,2.0,8.52478e-06,-0.15328048,0.058420766
NOTCH3 Activation and Transmission of Signal to the Nucleus,2.5958534e-05,2.0,2.5958534e-05,-0.14304352,0.06575976
NOTCH3 Intracellular Domain Regulates Transcription,2.3779063e-05,2.0,2.3779063e-05,-0.14432329,0.064842284
NOTCH4 Activation and Transmission of Signal to the Nucleus,0.0018783947,2.0,0.0018783947,0.9446917,0.8455709
NOTCH4 Intracellular Domain Regulates Transcription,2.0285564e-05,2.0,2.0285564e-05,-0.14637463,0.06337166
NR1D1 (REV-ERBA) represses gene expression,2.7372337e-06,2.0,2.7372337e-06,-0.15667887,0.055984415
Na+/Cl- dependent neurotransmitter transporters,3.2976216e-06,2.0,3.2976216e-06,-0.15634982,0.056220308
Neddylation,8.599759e-05,2.0,8.599759e-05,-0.10778908,0.09103413
Negative regulation of MET activity,7.963059e-07,2.0,7.963059e-07,-0.15781857,0.055167347
Negative regulation of NOTCH4 signaling,0.0010379807,2.0,0.0010379807,0.45120752,0.49178588
Negative regulation of TCF-dependent signaling by DVL-interacting proteins,6.016613e-07,2.0,6.016613e-07,-0.15793286,0.055085413
Negative regulation of TCF-dependent signaling by WNT ligand antagonists,1.552191e-06,2.0,1.552191e-06,-0.15737472,0.055485547
Negative regulation of the PI3K/AKT network,0.00021904599,2.0,0.00021904599,-0.029664159,0.14704289
Negative regulators of DDX58/IFIH1 signaling,3.385211e-05,2.0,3.385211e-05,-0.13840848,0.06908269
Nephrin family interactions,2.6412214e-05,2.0,2.6412214e-05,-0.14277712,0.06595076
Netrin mediated repulsion signals,2.4661347e-07,2.0,2.4661347e-07,-0.15814134,0.05493596
Neurexins and neuroligins,1.1797132e-07,2.0,1.1797132e-07,-0.1582169,0.05488179
Neurofascin interactions,8.1698704e-07,2.0,8.1698704e-07,-0.15780644,0.05517605
Neurophilin interactions with VEGF and VEGFR,0.0,2.0,0.0,-0.15828615,0.054832134
Neurotoxicity of clostridium toxins,5.725437e-07,9.0,6.3615964e-08,-0.1582488,-3.8120396
Neutrophil degranulation,9.0938636e-05,2.0,9.0938636e-05,-0.10488774,0.09311413
Nicotinate metabolism,2.616223e-06,2.0,2.616223e-06,-0.15674992,0.055933475
NoRC negatively regulates rRNA expression,4.6198608e-07,2.0,4.6198608e-07,-0.15801488,0.055026617
Nonhomologous End-Joining (NHEJ),0.0009805087,2.0,0.0009805087,0.41746047,0.46759224
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC),3.3086977e-08,2.0,3.3086977e-08,-0.15826672,0.054846056
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC),4.0384125e-06,2.0,4.0384125e-06,-0.15591483,0.056532167
Norepinephrine Neurotransmitter Release Cycle,2.4133118e-09,2.0,2.4133118e-09,-0.15828474,0.05483315
Notch-HLH transcription pathway,2.0379552e-07,2.0,2.0379552e-07,-0.1581665,0.05491792
NrCAM interactions,2.3894663e-07,2.0,2.3894663e-07,-0.15814584,0.054932717
Nuclear Receptor transcription pathway,2.504669e-08,2.0,2.504669e-08,-0.15827145,0.054842677
Nuclear signaling by ERBB4,0.0011727954,2.0,0.0011727954,0.53036964,0.54853827
O-glycosylation of TSR domain-containing proteins,5.489969e-06,2.0,5.489969e-06,-0.1550625,0.057143215
O-linked glycosylation of mucins,4.7599387e-05,2.0,4.7599387e-05,-0.1303362,0.07486982
Oncogene Induced Senescence,0.003624735,2.0,0.003624735,1.9701282,1.5807195
Orc1 removal from chromatin,0.00053537823,2.0,0.00053537823,0.15608352,0.28020775
Organic anion transporters,2.6427721e-11,2.0,2.6427721e-11,-0.15828614,0.054832146
Organic cation/anion/zwitterion transport,5.5394794e-05,3.0,5.5394794e-05,-0.1257588,-0.4742933
Other interleukin signaling,9.392398e-07,2.0,9.392398e-07,-0.15773465,0.05522752
Other semaphorin interactions,2.493939e-05,2.0,2.493939e-05,-0.14364195,0.06533075
Ovarian tumor domain proteases,0.0064284476,2.0,0.0064284476,3.616445,2.7609851
Oxidative Stress Induced Senescence,4.204989e-05,2.0,4.204989e-05,-0.13359481,0.07253367
PCP/CE pathway,0.00015611648,4.0,0.00015611648,-0.06661585,-0.9843376
PD-1 signaling,4.348767e-06,2.0,4.348767e-06,-0.1557326,0.056662813
PECAM1 interactions,7.7525995e-09,2.0,7.7525995e-09,-0.15828161,0.054835387
PI Metabolism,4.7190237e-08,14.0,3.3707312e-09,-0.15828417,-6.5744843
PI3K events in ERBB2 signaling,0.0001947641,2.0,0.0001947641,-0.043922286,0.13682105
PI3K events in ERBB4 signaling,3.9099253e-09,2.0,3.9099253e-09,-0.15828386,0.05483377
PIWI-interacting RNA (piRNA) biogenesis,3.9540066e-10,2.0,3.9540066e-10,-0.15828592,0.054832306
PKA activation in glucagon signalling,2.0431855e-06,2.0,2.0431855e-06,-0.15708642,0.05569224
PKA-mediated phosphorylation of key metabolic factors,3.416699e-08,2.0,3.416699e-08,-0.1582661,0.054846518
PKMTs methylate histone lysines,0.0002461135,2.0,0.0002461135,-0.013770349,0.15843736
PLCG1 events in ERBB2 signaling,4.922904e-06,2.0,4.922904e-06,-0.15539546,0.056904502
"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",6.856773e-07,2.0,6.856773e-07,-0.15788352,0.05512078
"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation",0.00042741693,2.0,0.00042741693,0.09268954,0.23475981
PP2A-mediated dephosphorylation of key metabolic factors,1.23038635e-05,2.0,1.23038635e-05,-0.15106142,0.060011636
PPARA activates gene expression,4.3674987e-11,2.0,4.3674987e-11,-0.15828612,0.054832157
PRC2 methylates histones and DNA,9.283736e-07,2.0,9.283736e-07,-0.15774101,0.055222947
PTEN Loss of Function in Cancer,0.0,2.0,0.0,-0.15828615,0.054832134
PTEN Regulation,3.2430003e-06,5.0,3.2430003e-06,-0.15638189,-1.6011369
PTK6 Activates STAT3,1.14865266e-07,2.0,1.14865266e-07,-0.1582187,0.054880485
PTK6 Down-Regulation,5.106067e-11,2.0,5.106067e-11,-0.15828612,0.054832157
PTK6 Expression,6.1931096e-06,2.0,6.1931096e-06,-0.1546496,0.05743922
PTK6 Regulates Cell Cycle,7.873471e-08,2.0,7.873471e-08,-0.15823993,0.05486527
PTK6 Regulates Proteins Involved in RNA Processing,9.568978e-06,2.0,9.568978e-06,-0.15266733,0.058860343
"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",0.00044835935,2.0,0.00044835935,0.10498675,0.24357584
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1,7.5486328e-06,2.0,7.5486328e-06,-0.15385365,0.05800984
PTK6 promotes HIF1A stabilization,4.4805767e-11,2.0,4.4805767e-11,-0.15828612,0.054832157
Packaging Of Telomere Ends,0.0011566082,2.0,0.0011566082,0.52086467,0.541724
Paradoxical activation of RAF signaling by kinase inactive BRAF,8.1880205e-07,2.0,8.1880205e-07,-0.15780535,0.05517682
Passive transport by Aquaporins,4.3875934e-05,2.0,4.3875934e-05,-0.13252257,0.07330237
Pentose phosphate pathway disease,0.0,5.0,0.0,-0.15828615,-1.602502
Peptide chain elongation,0.00018362177,2.0,0.00018362177,-0.05046497,0.1321305
Peroxisomal lipid metabolism,7.657003e-07,4.0,7.657003e-07,-0.15783654,-1.049735
Phase 0 - rapid depolarisation,2.7075239e-05,2.0,2.7075239e-05,-0.1423878,0.066229865
Phase 1 - inactivation of fast Na+ channels,4.050753e-08,2.0,4.050753e-08,-0.15826237,0.05484919
Phase 2 - plateau phase,0.0044622794,2.0,0.0044622794,2.4619274,1.9332967
Phase 3 - rapid repolarisation,3.6337205e-08,2.0,3.6337205e-08,-0.15826482,0.054847438
Phase 4 - resting membrane potential,3.0506221e-06,2.0,3.0506221e-06,-0.15649484,0.056116346
Phenylalanine and tyrosine catabolism,5.464465e-07,2.0,5.464465e-07,-0.15796529,0.055062167
Phenylketonuria,0.0,2.0,0.0,-0.15828615,0.054832134
Phosphate bond hydrolysis by NTPDase proteins,6.499959e-07,2.0,6.499959e-07,-0.15790448,0.05510576
Phosphorylation of CD3 and TCR zeta chains,2.4899876e-07,2.0,2.4899876e-07,-0.15813994,0.054936953
Physiological factors,3.5674298e-06,2.0,3.5674298e-06,-0.1561914,0.0563339
Pink/Parkin Mediated Mitophagy,0.0006131731,2.0,0.0006131731,0.20176403,0.3129567
Plasmalogen biosynthesis,6.334145e-08,2.0,6.334145e-08,-0.15824898,0.054858793
Platelet Adhesion to exposed collagen,0.00011850319,2.0,0.00011850319,-0.08870206,0.10471786
Platelet degranulation ,6.420737e-05,2.0,6.420737e-05,-0.120584115,0.081861205
Platelet sensitization by LDL,3.6511944e-06,2.0,3.6511944e-06,-0.1561422,0.056369152
Post-chaperonin tubulin folding pathway,1.7824968e-07,2.0,1.7824968e-07,-0.15818149,0.054907173
Post-transcriptional silencing by small RNAs,1.2403179e-07,2.0,1.2403179e-07,-0.15821332,0.054884344
Post-translational protein phosphorylation,1.6903896e-05,2.0,1.6903896e-05,-0.14836034,0.061948072
Potassium transport channels,7.380244e-07,2.0,7.380244e-07,-0.1578528,0.05514281
Pre-NOTCH Processing in Golgi,0.000778733,2.0,0.000778733,0.29897943,0.38265163
Pre-NOTCH Processing in the Endoplasmic Reticulum,6.428513e-09,2.0,6.428513e-09,-0.15828238,0.05483484
Pre-NOTCH Transcription and Translation,0.00044026837,2.0,0.00044026837,0.1002358,0.24016981
Presynaptic depolarization and calcium channel opening,1.9076155e-07,2.0,1.9076155e-07,-0.15817413,0.054912444
Processing and activation of SUMO,0.00019402753,4.0,0.00019402753,-0.044354796,-0.9683785
Processing of Intronless Pre-mRNAs,1.1039612e-05,2.0,1.1039612e-05,-0.15180379,0.059479423
Processing of SMDT1,0.00032073326,2.0,0.00032073326,0.030045766,0.18984967
Prolactin receptor signaling,3.010638e-08,2.0,3.010638e-08,-0.15826848,0.054844797
Proline catabolism,0.0,2.0,0.0,-0.15828615,0.054832134
Prostacyclin signalling through prostacyclin receptor,8.942127e-06,2.0,8.942127e-06,-0.15303542,0.05859646
Protein methylation,0.0011661071,2.0,0.0011661071,0.52644235,0.5457227
Protein repair,4.895491e-05,2.0,4.895491e-05,-0.12954023,0.075440444
Proton-coupled monocarboxylate transport,2.5022898e-10,2.0,2.5022898e-10,-0.158286,0.054832242
Proton-coupled neutral amino acid transporters,0.0,2.0,0.0,-0.15828615,0.054832134
Proton/oligopeptide cotransporters,2.0756293e-08,2.0,2.0756293e-08,-0.15827397,0.05484087
Purine catabolism,8.4727515e-07,2.0,8.4727515e-07,-0.15778865,0.055188805
Purine ribonucleoside monophosphate biosynthesis,4.3223288e-08,2.0,4.3223288e-08,-0.15826078,0.05485032
Purine salvage,0.00023183503,2.0,0.00023183503,-0.02215454,0.15242662
Pyrimidine biosynthesis,2.3631376e-06,2.0,2.3631376e-06,-0.15689854,0.05582693
Pyrimidine catabolism,2.0046033e-07,2.0,2.0046033e-07,-0.15816845,0.05491652
Pyrimidine salvage,6.2134063e-06,2.0,6.2134063e-06,-0.1546377,0.05744776
Pyrophosphate hydrolysis,2.1467004e-06,2.0,2.1467004e-06,-0.15702564,0.05573582
Pyruvate metabolism,0.0007025194,2.0,0.0007025194,0.25422743,0.35056835
RA biosynthesis pathway,4.13758e-05,2.0,4.13758e-05,-0.13399063,0.072249904
RAB GEFs exchange GTP for GDP on RABs,7.154317e-05,2.0,7.154317e-05,-0.1162766,0.08494932
RAB geranylgeranylation,0.00081148127,2.0,0.00081148127,0.31820893,0.39643756
RAF-independent MAPK1/3 activation,2.4662522e-06,3.0,2.4662522e-06,-0.15683798,-0.49657437
RAF/MAP kinase cascade,0.001802249,5.0,0.001802249,0.8999796,-0.8438178
RAS signaling downstream of NF1 loss-of-function variants,2.2992203e-06,2.0,2.2992203e-06,-0.15693606,0.05580003
RET signaling,1.7578849e-08,2.0,1.7578849e-08,-0.15827583,0.054839533
RHO GTPases Activate Formins,0.00029510353,2.0,0.00029510353,0.014996198,0.17906046
RHO GTPases Activate NADPH Oxidases,2.9181708e-09,2.0,2.9181708e-09,-0.15828444,0.054833356
RHO GTPases Activate ROCKs,0.00018394932,2.0,0.00018394932,-0.050272636,0.1322684
RHO GTPases Activate Rhotekin and Rhophilins,2.1356049e-05,2.0,2.1356049e-05,-0.14574607,0.06382228
RHO GTPases Activate WASPs and WAVEs,0.0007118688,2.0,0.0007118688,0.25971732,0.35450417
RHO GTPases activate CIT,0.00052486814,2.0,0.00052486814,0.14991207,0.27578336
RHO GTPases activate IQGAPs,2.4016572e-06,2.0,2.4016572e-06,-0.15687592,0.055843137
RHO GTPases activate KTN1,5.5833375e-06,2.0,5.5833375e-06,-0.15500766,0.05718252
RHO GTPases activate PAKs,1.3867201e-05,2.0,1.3867201e-05,-0.15014346,0.06066973
RHO GTPases activate PKNs,0.0009767121,2.0,0.0009767121,0.4152311,0.46599397
RHO GTPases regulate CFTR trafficking,1.679228e-08,2.0,1.679228e-08,-0.15827629,0.054839205
RMTs methylate histone arginines,2.2324492e-08,2.0,2.2324492e-08,-0.15827304,0.054841522
RNA Pol II CTD phosphorylation and interaction with CE,4.770527e-08,2.0,4.770527e-08,-0.15825814,0.054852217
RNA Polymerase I Chain Elongation,7.394279e-06,2.0,7.394279e-06,-0.1539443,0.057944864
RNA Polymerase I Promoter Escape,1.2392706e-05,2.0,1.2392706e-05,-0.15100926,0.060049027
RNA Polymerase I Promoter Opening,2.949034e-11,2.0,2.949034e-11,-0.15828614,0.054832146
RNA Polymerase I Transcription Initiation,2.8780864e-09,2.0,2.8780864e-09,-0.15828447,0.054833345
RNA Polymerase I Transcription Termination,2.2992235e-06,2.0,2.2992235e-06,-0.15693606,0.05580003
RNA Polymerase II Pre-transcription Events,2.5620816e-08,2.0,2.5620816e-08,-0.15827112,0.05484291
RNA Polymerase II Promoter Escape,1.4404004e-09,2.0,1.4404004e-09,-0.15828532,0.054832734
RNA Polymerase II Transcription Initiation,3.1356538e-07,2.0,3.1356538e-07,-0.15810204,0.054964133
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening,7.797781e-06,2.0,7.797781e-06,-0.15370736,0.05811473
RNA Polymerase III Abortive And Retractive Initiation,4.2578515e-05,2.0,4.2578515e-05,-0.1332844,0.0727562
RNA Polymerase III Chain Elongation,1.1250745e-05,2.0,1.1250745e-05,-0.1516798,0.05956831
RNA Polymerase III Transcription Initiation From Type 1 Promoter,3.871138e-07,2.0,3.871138e-07,-0.15805885,0.054995097
RNA Polymerase III Transcription Initiation From Type 2 Promoter,1.6685114e-07,2.0,1.6685114e-07,-0.15818818,0.05490237
RNA Polymerase III Transcription Initiation From Type 3 Promoter,8.097882e-07,2.0,8.097882e-07,-0.15781066,0.055173025
RNA Polymerase III Transcription Termination,7.4041195e-06,2.0,7.4041195e-06,-0.15393852,0.057949014
RNA polymerase II transcribes snRNA genes,6.675972e-07,2.0,6.675972e-07,-0.15789415,0.05511316
RNF mutants show enhanced WNT signaling and proliferation,2.0125715e-06,2.0,2.0125715e-06,-0.1571044,0.055679344
ROBO receptors bind AKAP5,8.7446494e-10,2.0,8.7446494e-10,-0.15828565,0.0548325
RORA activates gene expression,2.3642337e-05,2.0,2.3642337e-05,-0.14440358,0.06478474
"ROS, RNS production in phagocytes",8.424654e-06,2.0,8.424654e-06,-0.15333927,0.058378614
Rap1 signalling,0.0002398558,2.0,0.0002398558,-0.017444812,0.15580308
Receptor Mediated Mitophagy,7.2394334e-07,2.0,7.2394334e-07,-0.15786105,0.055136897
Receptor-type tyrosine-protein phosphatases,3.339909e-05,2.0,3.339909e-05,-0.13867448,0.06889199
Recognition of DNA damage by PCNA-containing replication complex,1.814609e-05,2.0,1.814609e-05,-0.14763092,0.06247101
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.00039186713,2.0,0.00039186713,0.071814984,0.21979457
Recycling pathway of L1,1.2104373e-06,2.0,1.2104373e-06,-0.1575754,0.055341683
Reduction of cytosolic Ca++ levels,7.336937e-06,2.0,7.336937e-06,-0.15397798,0.05792072
Reelin signalling pathway,3.9716386e-07,2.0,3.9716386e-07,-0.15805295,0.054999318
Regulated proteolysis of p75NTR,2.676286e-06,2.0,2.676286e-06,-0.15671468,0.05595875
Regulation of Complement cascade,0.00035999846,2.0,0.00035999846,0.053101968,0.20637897
Regulation of FZD by ubiquitination,2.0238073e-09,2.0,2.0238073e-09,-0.15828496,0.05483299
Regulation of HSF1-mediated heat shock response,9.2014365e-05,2.0,9.2014365e-05,-0.10425608,0.09356698
Regulation of Hypoxia-inducible Factor (HIF) by oxygen,7.439966e-05,4.0,7.439966e-05,-0.11459929,-1.0187377
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),3.1490174e-07,2.0,3.1490174e-07,-0.15810125,0.0549647
Regulation of KIT signaling,0.00016400771,2.0,0.00016400771,-0.061982185,0.12387367
Regulation of PAK-2p34 activity by PS-GAP/RHG10,4.4087516e-09,2.0,4.4087516e-09,-0.15828358,0.054833986
Regulation of TLR by endogenous ligand,3.925698e-08,2.0,3.925698e-08,-0.1582631,0.054848656
Regulation of TNFR1 signaling,2.3575594e-05,2.0,2.3575594e-05,-0.14444277,0.06475663
Regulation of actin dynamics for phagocytic cup formation,0.00029757243,2.0,0.00029757243,0.01644592,0.18009979
Regulation of activated PAK-2p34 by proteasome mediated degradation,5.9460604e-07,2.0,5.9460604e-07,-0.157937,0.05508244
Regulation of cholesterol biosynthesis by SREBP (SREBF),6.507169e-07,2.0,6.507169e-07,-0.15790407,0.05510606
Regulation of commissural axon pathfinding by SLIT and ROBO,1.4295709e-07,2.0,1.4295709e-07,-0.15820222,0.054892313
Regulation of cortical dendrite branching,0.0,2.0,0.0,-0.15828615,0.054832134
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,3.889204e-06,2.0,3.889204e-06,-0.15600245,0.05646935
Regulation of expression of SLITs and ROBOs,7.319853e-05,2.0,7.319853e-05,-0.11530459,0.08564616
Regulation of gap junction activity,5.640309e-06,2.0,5.640309e-06,-0.1549742,0.057206515
Regulation of gene expression in early pancreatic precursor cells,0.0,2.0,0.0,-0.15828615,0.054832134
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells,0.0,2.0,0.0,-0.15828615,0.054832134
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,7.811993e-06,2.0,7.811993e-06,-0.15369903,0.05812071
Regulation of innate immune responses to cytosolic DNA,0.0,2.0,0.0,-0.15828615,0.054832134
Regulation of necroptotic cell death,0.0018479578,2.0,0.0018479578,0.92681944,0.83275807
Regulation of ornithine decarboxylase (ODC),5.47629e-06,2.0,5.47629e-06,-0.15507053,0.057137463
Regulation of signaling by NODAL,3.5961496e-12,2.0,3.5961496e-12,-0.15828615,0.054832134
Release of Hh-Np from the secreting cell,4.8838177e-05,2.0,4.8838177e-05,-0.12960878,0.0753913
Release of apoptotic factors from the mitochondria,1.4252494e-07,2.0,1.4252494e-07,-0.15820247,0.05489213
Repression of WNT target genes,0.0007726663,2.0,0.0007726663,0.2954171,0.38009778
Resolution of AP sites via the multiple-nucleotide patch replacement pathway,1.0425821e-05,3.0,1.0425821e-05,-0.1521642,-0.4932237
Resolution of AP sites via the single-nucleotide replacement pathway,7.063233e-07,2.0,7.063233e-07,-0.15787141,0.055129465
Respiratory electron transport,0.0013431181,2.0,0.0013431181,0.6303817,0.6202382
Response of Mtb to phagocytosis,0.0,5.0,0.0,-0.15828615,-1.602502
Retinoid cycle disease events,3.5656662e-09,2.0,3.5656662e-09,-0.15828405,0.054833643
Retinoid metabolism and transport,3.469098e-08,2.0,3.469098e-08,-0.15826578,0.05484673
Retinoid metabolism disease events,0.0,2.0,0.0,-0.15828615,0.054832134
Retrograde transport at the Trans-Golgi-Network,0.00034851214,2.0,0.00034851214,0.046357296,0.20154363
Reversible hydration of carbon dioxide,0.00030486032,2.0,0.00030486032,0.02072531,0.18316773
Rhesus glycoproteins mediate ammonium transport.,3.3538472e-06,2.0,3.3538472e-06,-0.15631682,0.05624398
Rho GTPase cycle,1.6280084e-05,2.0,1.6280084e-05,-0.14872663,0.061685473
Role of ABL in ROBO-SLIT signaling,9.7749056e-05,2.0,9.7749056e-05,-0.100888714,0.09598108
Role of LAT2/NTAL/LAB on calcium mobilization,4.1336945e-05,2.0,4.1336945e-05,-0.13401344,0.07223355
Role of phospholipids in phagocytosis,2.3685236e-05,2.0,2.3685236e-05,-0.1443784,0.064802796
Role of second messengers in netrin-1 signaling,1.4295792e-08,2.0,1.4295792e-08,-0.15827776,0.054838143
SDK interactions,0.0,2.0,0.0,-0.15828615,0.054832134
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,2.5052938e-07,2.0,2.5052938e-07,-0.15813905,0.054937594
SHC1 events in EGFR signaling,4.0734936e-05,2.0,4.0734936e-05,-0.13436693,0.07198013
SHC1 events in ERBB2 signaling,0.00069733616,2.0,0.00069733616,0.25118387,0.3483864
SHC1 events in ERBB4 signaling,4.9103746e-05,2.0,4.9103746e-05,-0.12945284,0.075503096
SIRT1 negatively regulates rRNA expression,7.1102235e-08,2.0,7.1102235e-08,-0.1582444,0.054862063
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,3.3608827e-05,2.0,3.3608827e-05,-0.13855132,0.06898028
SLBP independent Processing of Histone Pre-mRNAs,1.9403024e-06,2.0,1.9403024e-06,-0.15714683,0.055648923
SLIT2:ROBO1 increases RHOA activity,4.498037e-07,2.0,4.498037e-07,-0.15802203,0.055021483
SRP-dependent cotranslational protein targeting to membrane,0.0005258616,2.0,0.0005258616,0.15049541,0.27620155
STING mediated induction of host immune responses,2.9950322e-06,3.0,2.9950322e-06,-0.15652749,-0.49635178
SUMO E3 ligases SUMOylate target proteins,0.0026551343,12.0,0.00022126119,-0.028363414,-4.3518953
Scavenging by Class A Receptors,1.4380234e-07,2.0,1.4380234e-07,-0.15820171,0.054892663
Scavenging by Class B Receptors,4.3444794e-05,2.0,4.3444794e-05,-0.13277572,0.073120885
Scavenging by Class F Receptors,7.199114e-07,2.0,7.199114e-07,-0.15786342,0.055135187
Scavenging by Class H Receptors,6.086628e-05,2.0,6.086628e-05,-0.12254598,0.080454715
Scavenging of heme from plasma,0.0021931513,2.0,0.0021931513,1.1295141,0.97807246
SeMet incorporation into proteins,9.57062e-06,2.0,9.57062e-06,-0.15266636,0.05886103
Selenocysteine synthesis,1.2815097e-05,2.0,1.2815097e-05,-0.15076125,0.06022684
Sema3A PAK dependent Axon repulsion,5.111254e-07,2.0,5.111254e-07,-0.15798603,0.055047296
Sema4D in semaphorin signaling,4.976239e-06,3.0,4.976239e-06,-0.15536416,-0.49551773
Senescence-Associated Secretory Phenotype (SASP),0.0010858418,2.0,0.0010858418,0.47931117,0.5119338
Sensing of DNA Double Strand Breaks,5.3285115e-05,2.0,5.3285115e-05,-0.12699758,0.07726332
Serine biosynthesis,6.434318e-05,2.0,6.434318e-05,-0.12050437,0.08191837
Serotonin Neurotransmitter Release Cycle,1.3933932e-07,2.0,1.3933932e-07,-0.15820433,0.054890793
Serotonin and melatonin biosynthesis,0.0,2.0,0.0,-0.15828615,0.054832134
Serotonin clearance from the synaptic cleft,7.7567663e-10,2.0,7.7567663e-10,-0.15828569,0.054832466
Signal regulatory protein family interactions,0.00045023905,2.0,0.00045023905,0.10609049,0.24436711
Signal transduction by L1,4.2982083e-06,2.0,4.2982083e-06,-0.15576228,0.056641527
Signaling by BMP,1.9437987e-06,2.0,1.9437987e-06,-0.15714478,0.0556504
Signaling by BRAF and RAF fusions,6.329723e-06,2.0,6.329723e-06,-0.15456939,0.057496734
Signaling by EGFRvIII in Cancer,3.2216394e-05,2.0,3.2216394e-05,-0.13936895,0.06839411
Signaling by FGFR1,0.007138027,5.0,0.007138027,4.0331044,1.4023594
Signaling by FGFR1 in disease,8.597707e-06,2.0,8.597707e-06,-0.15323766,0.058451474
Signaling by FGFR2,0.00038367702,5.0,0.00038367702,0.06700582,-1.4409873
Signaling by FGFR2 in disease,7.17114e-06,2.0,7.17114e-06,-0.15407532,0.057850935
Signaling by FGFR3,0.0017842554,4.0,0.0017842554,0.8894139,-0.29894778
Signaling by FGFR3 in disease,6.7579417e-06,3.0,6.7579417e-06,-0.15431795,-0.49476776
Signaling by FGFR4,5.7280024e-05,4.0,5.7280024e-05,-0.124651805,-1.0259444
Signaling by FGFR4 in disease,0.0,2.0,0.0,-0.15828615,0.054832134
Signaling by Hippo,1.0629918e-07,2.0,1.0629918e-07,-0.15822375,0.05487687
Signaling by Leptin,4.8887828e-06,2.0,4.8887828e-06,-0.1554155,0.05689013
Signaling by Ligand-Responsive EGFR Variants in Cancer,3.2883494e-05,2.0,3.2883494e-05,-0.13897724,0.06867493
Signaling by MST1,0.0,2.0,0.0,-0.15828615,0.054832134
Signaling by NOTCH1 HD Domain Mutants in Cancer,1.3670052e-05,2.0,1.3670052e-05,-0.15025923,0.06058674
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,2.4989475e-05,2.0,2.4989475e-05,-0.14361253,0.06535184
Signaling by NOTCH1 PEST Domain Mutants in Cancer,0.00012629385,2.0,0.00012629385,-0.084127456,0.10799745
Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,4.1024478e-07,2.0,4.1024478e-07,-0.15804526,0.055004835
Signaling by NTRK1 (TRKA),0.00046797775,9.0,5.199753e-05,-0.12775363,-3.6152782
Signaling by NTRK2 (TRKB),6.430794e-05,10.0,6.430794e-06,-0.15451005,-4.337654
Signaling by NTRK3 (TRKC),0.00011034983,6.0,0.00011034983,-0.093489654,-2.108493
Signaling by Overexpressed Wild-Type EGFR in Cancer,9.931042e-06,2.0,9.931042e-06,-0.15245473,0.05901275
Signaling by RAS mutants,6.850461e-07,2.0,6.850461e-07,-0.1578839,0.055120517
Signaling by high-kinase activity BRAF mutants,3.4892477e-05,2.0,3.4892477e-05,-0.13779758,0.06952065
Signaling by moderate kinase activity BRAF mutants,9.366131e-08,2.0,9.366131e-08,-0.15823115,0.05487156
Small interfering RNA (siRNA) biogenesis,2.6151227e-07,2.0,2.6151227e-07,-0.15813261,0.054942213
Smooth Muscle Contraction,0.009341417,2.0,0.009341417,5.3269167,3.987244
Sodium-coupled phosphate cotransporters,5.9953964e-10,2.0,5.9953964e-10,-0.1582858,0.05483239
"Sodium-coupled sulphate, di- and tri-carboxylate transporters",1.4694126e-07,2.0,1.4694126e-07,-0.15819988,0.05489399
Sodium/Calcium exchangers,1.6886202e-06,2.0,1.6886202e-06,-0.1572946,0.055542987
Sodium/Proton exchangers,0.021121882,2.0,0.021121882,12.244308,8.94641
Sperm Motility And Taxes,3.1793816e-09,2.0,3.1793816e-09,-0.15828429,0.05483346
Sperm:Oocyte Membrane Binding,3.438157e-08,2.0,3.438157e-08,-0.15826598,0.054846603
Sphingolipid de novo biosynthesis,3.0794323e-05,2.0,3.0794323e-05,-0.14020398,0.06779548
Stimulation of the cell death response by PAK-2p34,3.7170615e-08,2.0,3.7170615e-08,-0.15826434,0.054847777
Striated Muscle Contraction,3.1381447e-07,2.0,3.1381447e-07,-0.15810187,0.054964237
Surfactant metabolism,6.9245298e-06,2.0,6.9245298e-06,-0.15422013,0.05774711
Synaptic adhesion-like molecules,1.4010644e-05,2.0,1.4010644e-05,-0.15005922,0.060730122
Syndecan interactions,0.0010024845,2.0,0.0010024845,0.43036443,0.47684327
"Synthesis of IP2, IP, and Ins in the cytosol",0.00036507705,2.0,0.00036507705,0.056084074,0.20851687
Synthesis of IP3 and IP4 in the cytosol,0.00039280692,2.0,0.00039280692,0.072366826,0.22019018
Synthesis of IPs in the ER lumen,0.0,2.0,0.0,-0.15828615,0.054832134
Synthesis of IPs in the nucleus,2.2437494e-09,2.0,2.2437494e-09,-0.15828484,0.054833077
Synthesis of Ketone Bodies,8.4866684e-08,2.0,8.4866684e-08,-0.15823632,0.05486786
Synthesis of Lipoxins (LX),6.847139e-10,2.0,6.847139e-10,-0.15828575,0.054832425
Synthesis of active ubiquitin: roles of E1 and E2 enzymes,1.9641488e-05,2.0,1.9641488e-05,-0.14675285,0.06310051
Synthesis of diphthamide-EEF2,0.00021415761,2.0,0.00021415761,-0.032534573,0.14498504
Synthesis of dolichyl-phosphate mannose,9.8093735e-11,2.0,9.8093735e-11,-0.15828611,0.054832168
Synthesis of glycosylphosphatidylinositol (GPI),2.1441956e-06,2.0,2.1441956e-06,-0.1570271,0.05573476
Synthesis of pyrophosphates in the cytosol,1.6704507e-10,2.0,1.6704507e-10,-0.15828605,0.0548322
Synthesis of wybutosine at G37 of tRNA(Phe),3.332864e-07,2.0,3.332864e-07,-0.15809044,0.05497244
"Synthesis, secretion, and deacylation of Ghrelin",3.5086157e-06,2.0,3.5086157e-06,-0.15622593,0.056309137
"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",8.725904e-05,2.0,8.725904e-05,-0.10704836,0.09156515
"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",5.7449683e-06,2.0,5.7449683e-06,-0.15491275,0.057250567
TBC/RABGAPs,2.1247855e-05,2.0,2.1247855e-05,-0.14580959,0.06377674
TCF7L2 mutants don't bind CTBP,3.5916836e-09,2.0,3.5916836e-09,-0.15828405,0.054833643
"TET1,2,3 and TDG demethylate DNA",1.5753532e-10,2.0,1.5753532e-10,-0.15828606,0.05483219
TGF-beta receptor signaling activates SMADs,1.4889861e-06,2.0,1.4889861e-06,-0.15741184,0.055458944
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),1.3410645e-06,2.0,1.3410645e-06,-0.15749869,0.055396672
TICAM1 deficiency - HSE,0.0,2.0,0.0,-0.15828615,0.054832134
TLR3 deficiency - HSE,0.0,2.0,0.0,-0.15828615,0.054832134
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,2.7883647e-09,2.0,2.7883647e-09,-0.15828452,0.05483331
TNFR1-induced NFkappaB signaling pathway,0.0002101629,2.0,0.0002101629,-0.034880232,0.14330341
TNFR1-induced proapoptotic signaling,4.2880947e-06,2.0,4.2880947e-06,-0.15576822,0.056637272
TNFR1-mediated ceramide production,5.4851483e-07,2.0,5.4851483e-07,-0.15796407,0.055063035
TNFs bind their physiological receptors,4.4242327e-08,2.0,4.4242327e-08,-0.15826018,0.05485075
TRAF3 deficiency - HSE,4.0205292e-09,2.0,4.0205292e-09,-0.1582838,0.054833826
TRAF3-dependent IRF activation pathway,0.00019704932,2.0,0.00019704932,-0.042580422,0.13778305
TRAF6 mediated IRF7 activation,1.6683456e-05,2.0,1.6683456e-05,-0.14848977,0.061855286
TRAF6 mediated NF-kB activation,2.8937155e-05,2.0,2.8937155e-05,-0.1412945,0.06701367
TRAIL  signaling,9.35446e-05,2.0,9.35446e-05,-0.10335754,0.09421115
TRP channels,0.00040068512,2.0,0.00040068512,0.07699284,0.22350663
TWIK related potassium channel (TREK),0.0,2.0,0.0,-0.15828615,0.054832134
TWIK-related alkaline pH activated K+ channel (TALK),0.0,2.0,0.0,-0.15828615,0.054832134
TWIK-related spinal cord K+ channel (TRESK),0.0,2.0,0.0,-0.15828615,0.054832134
TWIK-releated acid-sensitive K+ channel (TASK),0.0,2.0,0.0,-0.15828615,0.054832134
TYSND1 cleaves peroxisomal proteins,0.0041031595,2.0,0.0041031595,2.2510552,1.7821196
Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK),2.6941316e-07,2.0,2.6941316e-07,-0.15812796,0.054945547
Tandem pore domain halothane-inhibited K+ channel (THIK),0.0,2.0,0.0,-0.15828615,0.054832134
Terminal pathway of complement,0.0,2.0,0.0,-0.15828615,0.054832134
Termination of translesion DNA synthesis,1.1546916e-05,2.0,1.1546916e-05,-0.1515059,0.05969298
"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",7.892121e-06,2.0,7.892121e-06,-0.15365197,0.05815443
The activation of arylsulfatases,6.5152795e-05,2.0,6.5152795e-05,-0.12002897,0.08225919
Threonine catabolism,3.8091034e-07,2.0,3.8091034e-07,-0.15806249,0.054992475
Thrombin signalling through proteinase activated receptors (PARs),0.00010961105,2.0,0.00010961105,-0.09392345,0.10097458
Thromboxane signalling through TP receptor,2.2195299e-07,2.0,2.2195299e-07,-0.15815583,0.054925565
Thyroxine biosynthesis,2.7330227e-10,2.0,2.7330227e-10,-0.158286,0.054832242
Tie2 Signaling,1.42250745e-08,2.0,1.42250745e-08,-0.1582778,0.054838125
Tight junction interactions,1.4953453e-06,2.0,1.4953453e-06,-0.15740809,0.05546162
Toll Like Receptor 10 (TLR10) Cascade,0.0,1.0,0.0,-0.15828615,0.6072769
Toll Like Receptor 2 (TLR2) Cascade,0.0,1.0,0.0,-0.15828615,0.6072769
Toll Like Receptor 3 (TLR3) Cascade,7.100376e-05,7.0,7.100376e-05,-0.11659334,-2.6775012
Toll Like Receptor 4 (TLR4) Cascade,0.0001424613,3.0,0.0001424613,-0.07463406,-0.43764132
Toll Like Receptor 5 (TLR5) Cascade,0.0,1.0,0.0,-0.15828615,0.6072769
Toll Like Receptor 7/8 (TLR7/8) Cascade,2.1236874e-05,2.0,2.1236874e-05,-0.14581604,0.06377211
Toll Like Receptor 9 (TLR9) Cascade,1.04471865e-05,2.0,1.04471865e-05,-0.15215164,0.059230037
Trafficking and processing of endosomal TLR,3.9300733e-07,2.0,3.9300733e-07,-0.15805538,0.054997575
Trafficking of myristoylated proteins to the cilium,1.0086096e-08,2.0,1.0086096e-08,-0.15828022,0.05483638
Transcriptional Regulation by E2F6,1.4735276e-06,2.0,1.4735276e-06,-0.15742092,0.055452432
Transcriptional Regulation by TP53,2.8376647e-07,6.0,2.8376647e-07,-0.15811953,-2.154827
Transcriptional activation of mitochondrial biogenesis,6.795117e-05,2.0,6.795117e-05,-0.11838579,0.08343721
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.00091245014,4.0,0.00091245014,0.37749702,-0.6659475
Transcriptional regulation by RUNX1,9.370011e-06,13.0,7.2077006e-07,-0.15786293,-6.0181146
Transcriptional regulation by RUNX2,1.5451071e-06,5.0,1.5451071e-06,-0.15737888,-1.6018516
Transcriptional regulation by RUNX3,1.1137823e-07,10.0,1.1137823e-08,-0.15827961,-4.3646784
Transcriptional regulation by small RNAs,2.8698778e-07,2.0,2.8698778e-07,-0.15811764,0.054952946
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,1.7153663e-07,7.0,1.7153663e-07,-0.15818542,-2.7073193
Transcriptional regulation of white adipocyte differentiation,7.5307153e-06,2.0,7.5307153e-06,-0.15386419,0.058002293
Transferrin endocytosis and recycling,0.0037788479,2.0,0.0037788479,2.060622,1.6455957
Translesion Synthesis by POLH,8.170657e-09,2.0,8.170657e-09,-0.15828136,0.05483558
Translesion synthesis by POLI,2.926608e-06,2.0,2.926608e-06,-0.15656768,0.056064125
Translesion synthesis by POLK,4.4665694e-06,2.0,4.4665694e-06,-0.15566343,0.056712404
Translesion synthesis by REV1,2.500543e-06,2.0,2.500543e-06,-0.15681785,0.055884775
Translocation of SLC2A4 (GLUT4) to the plasma membrane,1.5729639e-06,2.0,1.5729639e-06,-0.15736252,0.055494294
Translocation of ZAP-70 to Immunological synapse,3.7201794e-08,2.0,3.7201794e-08,-0.15826431,0.054847788
Transport and synthesis of PAPS,1.0853719e-07,2.0,1.0853719e-07,-0.15822242,0.054877814
Transport of Mature mRNA derived from an Intron-Containing Transcript,0.0008219156,2.0,0.0008219156,0.32433587,0.40083003
Transport of Mature mRNAs Derived from Intronless Transcripts,6.530694e-07,4.0,6.530694e-07,-0.15790269,-1.0497824
Transport of fatty acids,2.697332e-05,2.0,2.697332e-05,-0.14244765,0.06618696
Transport of glycerol from adipocytes to the liver by Aquaporins,0.0,2.0,0.0,-0.15828615,0.054832134
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,1.0908728e-06,2.0,1.0908728e-06,-0.15764561,0.055291343
Transport of nucleotide sugars,3.1857733e-05,2.0,3.1857733e-05,-0.13957955,0.06824312
Transport of organic anions,2.0952575e-06,2.0,2.0952575e-06,-0.15705584,0.055714168
Transport to the Golgi and subsequent modification,8.922597e-06,3.0,8.922597e-06,-0.15304688,-0.49385646
Triglyceride biosynthesis,1.3774734e-06,2.0,1.3774734e-06,-0.1574773,0.055412006
Triglyceride catabolism,8.242942e-07,2.0,8.242942e-07,-0.15780213,0.05517914
"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",5.3317885e-06,2.0,5.3317885e-06,-0.15515538,0.057076637
Tryptophan catabolism,6.711173e-08,2.0,6.711173e-08,-0.15824674,0.054860383
Type I hemidesmosome assembly,8.546002e-07,2.0,8.546002e-07,-0.15778434,0.055191886
UCH proteinases,7.769694e-06,2.0,7.769694e-06,-0.15372385,0.058102906
UNC93B1 deficiency - HSE,0.0,2.0,0.0,-0.15828615,0.054832134
Ub-specific processing proteases,0.007028521,2.0,0.007028521,3.9688032,3.0135953
Ubiquinol biosynthesis,7.267814e-06,2.0,7.267814e-06,-0.15401855,0.05789163
Ubiquitin-dependent degradation of Cyclin D,0.00010233992,2.0,0.00010233992,-0.098193,0.097913675
Unwinding of DNA,7.574877e-05,2.0,7.574877e-05,-0.113807105,0.08671973
Uptake and function of anthrax toxins,1.504543e-06,2.0,1.504543e-06,-0.1574027,0.0554655
Uptake and function of diphtheria toxin,2.739036e-07,2.0,2.739036e-07,-0.15812533,0.05494743
Urea cycle,3.0271096e-05,2.0,3.0271096e-05,-0.14051121,0.06757522
Utilization of Ketone Bodies,1.7201332e-08,2.0,1.7201332e-08,-0.15827605,0.054839373
VEGF ligand-receptor interactions,2.2915663e-07,2.0,2.2915663e-07,-0.1581516,0.0549286
VEGFA-VEGFR2 Pathway,0.0003077156,3.0,0.0003077156,0.022401912,-0.368075
VLDL assembly,0.0,2.0,0.0,-0.15828615,0.054832134
VLDL clearance,0.00018546742,2.0,0.00018546742,-0.04938122,0.13290747
VLDLR internalisation and degradation,0.00025911524,2.0,0.00025911524,-0.0061358246,0.16391064
Variant SLC6A14 may confer susceptibility towards obesity,0.0,2.0,0.0,-0.15828615,0.054832134
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,2.0,0.0,-0.15828615,0.054832134
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,2.0,0.0,-0.15828615,0.054832134
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,2.0,0.0,-0.15828615,0.054832134
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,2.0,0.0,-0.15828615,0.054832134
Vasopressin regulates renal water homeostasis via Aquaporins,0.00013943342,2.0,0.00013943342,-0.076412,0.11352876
Vitamin B1 (thiamin) metabolism,2.0396461e-10,2.0,2.0396461e-10,-0.15828604,0.05483222
Vitamin B2 (riboflavin) metabolism,7.107401e-05,2.0,7.107401e-05,-0.116552085,0.084751815
Vitamin B5 (pantothenate) metabolism,7.354923e-07,2.0,7.354923e-07,-0.15785429,0.05514174
Vitamin C (ascorbate) metabolism,8.290006e-06,2.0,8.290006e-06,-0.15341835,0.058321927
Vitamin D (calciferol) metabolism,5.5365706e-07,2.0,5.5365706e-07,-0.15796104,0.055065203
Vitamin E,0.0,2.0,0.0,-0.15828615,0.054832134
Vitamins B6 activation to pyridoxal phosphate,5.702611e-08,2.0,5.702611e-08,-0.15825267,0.05485613
Voltage gated Potassium channels,5.674296e-08,2.0,5.674296e-08,-0.15825284,0.05485602
VxPx cargo-targeting to cilium,0.00020741922,2.0,0.00020741922,-0.036491305,0.1421484
WNT ligand biogenesis and trafficking,3.0021815e-06,2.0,3.0021815e-06,-0.1565233,0.056095947
WNT ligand secretion is abrogated by the PORCN inhibitor LGK974,0.0,2.0,0.0,-0.15828615,0.054832134
WNT mediated activation of DVL,6.9388e-05,2.0,6.9388e-05,-0.117542095,0.08404207
Wax biosynthesis,2.3677031e-09,2.0,2.3677031e-09,-0.15828477,0.054833118
"XAV939 inhibits tankyrase, stabilizing AXIN",1.0519807e-10,2.0,1.0519807e-10,-0.15828608,0.05483218
XBP1(S) activates chaperone genes,0.0027981952,2.0,0.0027981952,1.484791,1.232775
YAP1- and WWTR1 (TAZ)-stimulated gene expression,8.8239527e-10,2.0,8.8239527e-10,-0.15828565,0.0548325
ZBP1(DAI) mediated induction of type I IFNs,1.0627283e-08,3.0,1.0627283e-08,-0.15827991,-0.4976081
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,1.0310638e-05,3.0,1.0310638e-05,-0.15223183,-0.49327216
cGMP effects,1.8323919e-05,2.0,1.8323919e-05,-0.1475265,0.062545866
eNOS activation,3.800054e-05,2.0,3.800054e-05,-0.13597256,0.07082904
mRNA 3'-end processing,2.8287835e-05,2.0,2.8287835e-05,-0.14167577,0.066740334
mRNA Capping,0.0001504756,2.0,0.0001504756,-0.06992813,0.11817712
mRNA Splicing - Major Pathway,7.555398e-05,2.0,7.555398e-05,-0.113921486,0.08663773
mRNA Splicing - Minor Pathway,2.6556932e-05,2.0,2.6556932e-05,-0.14269215,0.066011675
mRNA decay by 3' to 5' exoribonuclease,1.1551109e-06,2.0,1.1551109e-06,-0.15760788,0.055318385
mRNA decay by 5' to 3' exoribonuclease,9.123273e-08,2.0,9.123273e-08,-0.15823258,0.054870542
mTORC1-mediated signalling,3.1543254e-06,2.0,3.1543254e-06,-0.15643395,0.05615999
p130Cas linkage to MAPK signaling for integrins,0.0020459166,2.0,0.0020459166,1.0430592,0.91609186
p53-Dependent G1/S DNA damage checkpoint,3.5922116e-05,2.0,3.5922116e-05,-0.13719298,0.0699541
p53-Independent G1/S DNA damage checkpoint,8.195968e-07,2.0,8.195968e-07,-0.15780489,0.055177152
p75NTR negatively regulates cell cycle via SC1,2.73615e-06,2.0,2.73615e-06,-0.15667951,0.055983953
p75NTR regulates axonogenesis,1.4300277e-06,3.0,1.4300277e-06,-0.15744646,-0.4970106
p75NTR signals via NF-kB,0.00018016643,3.0,0.00018016643,-0.052493915,-0.42176878
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex,2.3294324e-05,5.0,2.3294324e-05,-0.14460792,-1.5926958
rRNA modification in the mitochondrion,7.559208e-07,2.0,7.559208e-07,-0.1578423,0.055150345
rRNA modification in the nucleus and cytosol,7.1966696e-07,2.0,7.1966696e-07,-0.15786357,0.05513509
snRNP Assembly,0.0004721976,2.0,0.0004721976,0.11898437,0.2536109
tRNA modification in the mitochondrion,4.5320653e-06,2.0,4.5320653e-06,-0.15562496,0.05673998
tRNA processing in the mitochondrion,1.2811496e-06,2.0,1.2811496e-06,-0.15753387,0.055371452
tRNA processing in the nucleus,3.2080654e-05,2.0,3.2080654e-05,-0.13944866,0.06833697
truncated APC mutants destabilize the destruction complex,7.0690665e-05,3.0,7.0690665e-05,-0.116777174,-0.4678543
via Death Receptors in the presence of ligand,4.4556156e-05,3.0,4.4556156e-05,-0.13212314,-0.47885603
via Dependence Receptors in the absence of ligand,8.811817e-06,2.0,8.811817e-06,-0.15311192,0.058541607
